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ABSTRACT 
 
Frontotemporal dementia (FTD) accounts for a variable degree of degenerative diseases, ranging between 
7 and 15% in different countries, and its symptoms can overlap with those of AD and other dementias. 
Magnetic resonance (MR) imaging has proved useful in supporting the clinical evaluation during the 
diagnostic process. Different techniques have been used to quantify brain atrophy on MR images, from 
manual tracing of regions of interest, to the most recent voxel-based morphometry (VBM), that allows 
analysis of the whole brain in one comparison, without previous defining of regions of interest. 
The goals of this study were to use both traditional and novel methods for quantification of gray matter 
atrophy in FTD in order to deepen the current knowledge of the disease, to improve the differential 
diagnosis with AD or other dementias, and to try to understand the pathogenesis of this condition. 
Existing MR images from 10 FTD subjects, 27 AD and 27 controls were compared with traditional 
methods for quantification of brain atrophy using manual or semiautomatic tracing of the regions of 
interest (ROI), or with voxel by voxel comparison of MR images normalized on a template, using the 
SPM99 program. 
Using manual and semiautomatic tracing a differential pattern of atrophy in FTD and AD has been 
defined through a set of relevant ROIs: frontal brain and horns, temporal brain and horns, and 
hippocampus. This pattern could separate the two patient groups with 90% sensitivity and 93% 
specificity. 
Manual tracing of the amygdala allowed to investigate the nature of the different behavioral disturbances 
in AD and FTD. FTD patients were found to exhibit less amygdaloid atrophy than AD patients, therefore 
the greater prevalence of amygdaloid-related symptoms usually reported in FTD patients has been 
interpreted as being a consequence of the disconnection of fronto-limbic circuitry in these patients. 
The pattern of atrophy in single patients has been investigated in order to isolate possible subtypes of 
FTD. Two patterns of atrophy were isolated, a symmetric, and an asymmetric pattern, depending on the 
distribution of atrophy (similar or unbalanced between the right and left lobes). The “symmetric” patients 
had lower age at onset and more severe atrophy than the “asymmetric” ones. Moreover, findings from this 
study point to a possible role of the APOE genotype in modulating the distribution of atrophy in FTD, 
since 100% of the ε4 alleles were found in the subgroup of patients with symmetric atrophy. The 
investigation of the role of APOE in FTD was deepened using the SPM99 program to compare the 
patients carrying the ε4 allele with the non carriers. FTD patients carrying the ε4 allele exhibited more 
right frontotemporal atrophy than the non carriers. The same analysis was also carried out in the AD 
patients: the ε4 carriers exhibited more medial-temporal atrophy than the non carriers. These results were 
interpreted as indicating that the ε4 carriers have higher brain vulnerability and this probably interacts 
with the specific effects of the disease, increasing atrophy in the typically affected regions.  
Finally, a general analysis of the entire pattern of atrophy was carried out with SPM99 comparing FTD 
patients with controls. This analysis detected the involvement of the whole rostral limbic system, a circuit 
known to be involved in tuning and monitoring the behavioral output. This is consistent with the 
behavioral picture of FTD and with recent findings describing cognition and social competence in these 
patients. 
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1. INTRODUCTION 
 
The large increase in the incidence of the degenerative dementias observed in the last 
decades has sharpened the clinical discrimination of their different forms, but the 
evaluation of individual cases still is subject to error. The overlap between different 
kinds of dementia is variable and constitutes a source of uncertainty that clinicians 
would wish to rule out, especially should specific therapies become available with 
selective effects on these conditions. At present, discrimination of the different 
degenerative conditions and clarification of their clinical characterization and 
pathogenesis is also necessary to permit focus allocation of financial resources to 
interventions thus maximizing the benefits of this intervention. A number of treatments 
are available for Alzheimer’s disease (AD), ranging from molecules modifying the 
pathogenetic mechanisms of disease to behavioral and rehabilitative interventions. The 
same treatments are not equally efficacious in frontotemporal dementia (FTD), nor are 
there as many alternatives available for treatment of these patients. On the other hand, 
their behavioral problems may require allocation of resources for special care.  
Insight into the pathogenesis of Alzheimer’s disease is more advanced than in FTD, as 
can be judged by the greater availability of different kinds of therapies. A deeper insight 
into the pathogenesis of FTD might not only improve the allocation of resources for 
providing the available treatments, but might also help the development of new specific 
therapies for this debilitating disease. 
FTD is diagnosed primarily as a behavioral syndrome accompanied by a cognitive 
involvement mainly characterized by impairment of frontal components. Memory and 
other cognitive functions can also be impaired, but the behavioral disturbances are more 
prominent and constitute the main feature distinguishing FTD from other more frequent 
causes of dementia, such as AD. In the diagnostic process, especially the differential 
diagnosis of FTD, neuroimaging provides a particularly useful tool. In fact, the clinical 
evaluation of some functions may not be possible due to the typical lack of motivation 
of FTD patients. Moreover, the typical tendency of FTD to impoverishment of 
language, or even to mutism, leads to a decline in performance that cannot be 
interpreted unequivocally as a true impairment of the tested functions. The combination 
of clinical and neuroimaging evaluations maximizes the accuracy of the diagnostic 
process. Imaging tools may also provide information which partially overlaps between 
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these different diseases, but with careful selection, these tools can add value to the 
diagnostic process. 
Even in the clinical setting alone many ambiguities have existed for long years. AD has 
been traditionally considered as a disease of the limbic structures, since the medial 
temporal regions are involved. Nonetheless, the important disturbance of adaptive 
behavior in FTD patients, as well as their severe lack of motivation and emotional 
involvement in social interactions leads one to wonder whether this is not much more a 
“limbic” disease than AD. Work by Damasio (Damasio, 1995) combined “frontal” 
functions and limbic components into a global interpretation of human brain 
functioning, and recently most sectors of basic neuroscience are supporting this kind of 
approach, and adopting it to explain experimental data and human behavior. These 
concepts might find larger use also in clinical settings, and provide a concrete 
improvement in both the differential diagnosis and pathogenetic explanations of 
diseases.  
This work covers only a limited part of this overall goal, i.e. the use of MRI techniques 
in the diagnosis and in the explanation of some clinical correlates. Nonetheless, it does 
try to gather new concepts to explain neuroimaging and clinical findings, possibly 
providing additional lines of research that might assist in the investigation of 
pathogenetic mechanisms of FTD. 
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2. REVIEW OF THE LITERATURE 
 
2.1 Historical account 
 
The identification of FTD has its historical roots in the studies of Arnold Pick, head of 
the Department of Psychiatry, University of Prague, at the end of the nineteenth 
century. The clinical characterization of Pick’s patients relied on the cognitive decline 
associated with marked behavioral and language disturbances. Gross anatomic post 
mortem observation showed global brain atrophy, but degeneration was more severe in 
the left lobe. At the time, the notion that brain degeneration might be unbalanced in its 
distribution, rather than homogenously diffuse in the brain, was new, and this 
constituted the main finding of Pick. Other similar cases were described by Richter 
(Richter, 1918), Lüers and Spatz (Lüers and Spatz, 1957) and Tissot (Tissot, 1975). 
The histological characterization of Pick’s disease was carried out in 1911 by Alois 
Alzheimer, who described the “Pick’s bodies”, “Pick’s cells”, and the cortical 
spongiosis. Plaques and neurofibrillary tangles were not observed in the brain tissue of 
these patients, which confirmed the peculiar characterization of this nosological entity 
(Alzheimer, 1911). 
The denomination “Pick’s disease” was introduced by Gans in 1922, referring to this set 
of observations, and acknowledging Pick’s initial description. Gans emphasized that a 
marked frontal atrophy was generally compromised in all lobar atrophy diseases 
accompanied by aspontaneity and disorders of attention, behavior and language. (Gans, 
1922) 
In 1927, the first separation between frontal and temporal involvement was theorized by 
Schneider. He observed that the pathologic involvement of the temporal lobe was 
associated with language disturbances, while apathy characterized those patients with 
frontal atrophy (Schneider, 1927). The term “Pick’s disease” was used for both of these 
patterns of atrophy. Nonetheless, it was observed in these years that the Pick’s bodies or 
cells might not be present at the histopathological examination (Schneider, 1927;1929).  
In 1975 Tissot described a series of 32 patients with clinical and pathological 
assessment, where patients were divided into three groups based on pathological 
findings: the first group showing both Pick bodies and Pick cells, the second group had 
only Pick cells, and the third group exhibited no Pick pathology. 
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The clinical picture was characterized by mood, language, attention and behavioral 
disorders which were evident from the initial stages of disease. Motor function could be 
slower, and increasingly impaired in subsequent stages of disease. A greater 
involvement of language was also described in these later stages, while the cognitive 
impairment consisted mainly in planning and orientation deficits. Behavioral problems 
extended to eating behavior, and alteration in blood pressure values were registered 
(Tissot, 1975).  
More recently, researchers from Manchester, UK (Neary et al., 1998) and Lund, 
Sweden (Gustafson, Risberg, Brun, Englud, 1987) described this type of lobar atrophy 
as an entity separate from AD. They also observed that the typical Pick bodies could be 
present, but were absent from the majority of the cases with frontal lobe degeneration. 
About 10% of patients with organic dementia presented with unspecific gray matter 
degeneration without any histological Alzheimer or Pick pathology. Neuropathology 
was evident at the microscopical investigation more than at gross inspection, and 
consisted of neuronal loss, gliosis and spongiosis mainly involving laminae 1-3.  
White matter changes were less severe, and roughly corresponded to the distribution of 
the cortical degeneration, being probably its consequence. The clinical picture was 
characterized by a positive family history for dementia (50%, versus 30% reported for 
other kinds of dementia), insidious onset with an early change of personality, lack of 
insight, disinhibition, emotional lability, and other behavioral symptoms. The 
behavioral picture was accompanied by a frequent involvement of speech, with 
symptoms ranging from stereotyped phrases and echolalia to mutism. Altered dietary 
and oral behavior were detected as secondary symptoms. Sparing of memory and spatial 
ability discriminated this kind of dementia from AD. Regional cerebral blood flow 
recordings available for a group of these autopsied patients confirmed severely 
decreased values in the prefrontal regions, which were even more pronounced in the 
Pick patients. 
 
 
2.2 Consensus criteria 
 
In 1994 the first consensus statement was produced based on the clinical evaluation of a 
very large sample of patients, and on the pathological observation of 60 of them. The 
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document was meant to agree on a common definition of frontotemporal dementia, 
intended to characterize the non-Alzheimer lobar atrophy described by the Lund and 
Manchester groups. 
In these first criteria, the clinical picture of frontotemporal dementia was depicted as a 
set of core and supportive diagnostic features. Most core features had long been 
described, such as emotional unconcern, behavioral and speech disorders. A more 
complete description of behavioral disturbances, delineating a wide impairment of the 
diverse frontal functions, was provided. Supportive features like presenile age at onset 
of disease and a positive family history of similar condition were also reported. Overall, 
clinical features described correspond to the FTD type of frontotemporal dementia, as 
reported by the successively defined criteria (Neary et al, 1998). The Authors stated in 
this report that progressive aphasia shows a spectrum of histological changes 
overlapping with that of FTD, but with more posterior distribution in the temporal 
cortex, and that features of that condition were not discussed in that consensus 
statement. With respect to the pathological characteristics, the cases were separated into 
three categories: one with Pick-type pathology, one lacking distinctive histopathology, 
one with evidence of motor neuron disease (Lund and Manchester groups, 1994). As to 
the type lacking distinctive histopathology the Authors report that, in cases with 
particularly pronounced behavioral aberrations, and, in particular, greater frequency of 
stereotypic behaviors, atrophy of the amygdala, striatum, and hippocampus is more 
evident than neocortical atrophy, and suggest that this may represent a clinical subtype. 
On the other hand, Pick’s disease was described, from a pathological point of view, as 
characterized by cortical atrophy with similar distribution, but more intense and 
circumscribed. The same was reported for cortical atrophy in FTD with motor-neuron 
disease, that had, in addition, involvement of motor neurons. 
In 1998, these criteria were revised in order to account for two clinical profiles that 
share a number of features with frontotemporal dementia, but present more marked 
language disturbances, and less important behavioral deficits, at least during initial 
stages of disease: progressive non fluent aphasia (PA) and semantic dementia (SD). 
Together with the clinical subtype characterized by behavioral disturbances, and termed 
frontotemporal dementia (FTD), this set of conditions was globally named 
frontotemporal lobar degeneration (FTLD), in order to account for the distribution of 
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the neuropathological changes, that affect the frontal and temporal lobes. In this 
consensus criteria, the Authors stated that the relative severity and distribution of such 
fronto-temporal atrophy give rise to the three different syndromes, posterior temporal 
atrophy being associated with the two subtypes mainly involving language, but the kind 
of histological changes underlying them are basically two. One consists in 
microvacuolar changes without specific histological features, the other in severe 
astrocytic gliosis with or without ballooned cells and inclusion bodies (Pick type). 
Nonetheless, pathological data were not further discussed, nor were they associated to 
distinct clinical subtypes in these criteria. . 
Clinically, all of these conditions were described as presenting with insidious onset and 
gradual progression. PA was defined as being characterized by nonfluent spontaneous 
speech associated with anomia or agrammatism or phonemic paraphasias. Supportive 
features list other language impairment, such as impaired repetition or alexia, and early 
preservation of social skills, that eventually decline resembling the typical pattern of 
FTD.  
SD is described as being characterized by loss of word meaning, manifesting in 
impaired naming and comprehension, and fluent but empty spontaneous speech. 
Semantic paraphasias or agnosia for objects or familiar faces could accompany these 
symptoms, while preserved repetition distinguished SD from PA. In contrast to PA, 
behavior can be impaired early, but this feature is not strictly required for diagnosis. 
Finally, FTD was defined as being primarily characterized by the early decline in 
personal and social conduct, emotional blunting and loss of insight. A typical pattern of 
impaired frontal functions was supportive in the diagnosis, as well as speech deficits 
and physical signs, ranging from primitive reflexes to labile blood pressure (Neary et 
al., 1998).  
Most recently, the clinical and pathological criteria were reassessed at the 
Frontotemporal Dementia and Pick’s Disease Criteria Conference in Bethesda, 2000 
(McKhann et al., 2001), where the definition of the disease bended to the side of 
pathological aspects rather than of the clinical ones. The main conclusion of this work 
was that it is not possible, at present, to fit the different phenotypes of FTLD with 
different pathological characterization, and therefore the different phenotypes should be 
collectively referred to as FTD. The authors recognized that the different phenotypes 
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previously described as PA and SD do differ from the behavioral variant of the disease, 
but that there is not sufficient evidence to separate these conditions nosologically. From 
a clinical point of view, the Work Group of McKhann and collaborators rather 
distinguished among two clinical phenotypes, one mainly involving behavior, the other 
affecting language (McKhann et al., 2001). The Authors underline that in the research 
community the terms primary progressive aphasia and semantic dementia are 
commonly adopted, “although the changes in language may be the initial presentation of 
the disease” but, “as the disease progresses, behavioral changes may occur”. Therefore, 
they state that ”patients with FTD present with 2 patterns: gradual and progressive 
changes in behavior, or gradual and progressive language dysfunction”, these being core 
clinical features whether they have early presentation, and a level of severity that 
interferes with the normal social or occupational functioning. Main differential features 
distinguishing from AD are summarized by the Work Group mainly in differences in 
the age at onset (rarely after 75 for FTD), in selectively preserved orientation and ability 
to track recent events, lack of concern for own condition, and greater risk for motor 
abnormalities.  
Of particular interest, the Work Group delineated neuropathological recommendations 
for evaluation of the condition. First of all, it is stated that neither severity, nor 
distribution of atrophy has been observed to be constantly associated to any of the 
considered clinical conditions. Microscopic examination using histochemical and 
immunohistochemical methods, besides using typical tools able to exclude AD or LBD 
pathology, should carry out biochemical analysis of the insoluble tau, conjoined with 
testing for ubiquitin, required because some characteristic lesions are negative to tau, 
but positive to ubiquitin. Finally, the basic distinction allowed by pathological 
examination distinguishes between tau-positive inclusions and presence of insoluble 
tau, tau- or ubiquitin-negative inclusion without detectable insoluble tau, and tau-
negative but ubiquitin-positive inclusions, without detectable insoluble tau. Within this 
framework, tau-positive conditions seem to gather the clinical diagnoses of corticobasal 
degeneration, progressive supranuclear palsy, Pick’s disease, frontotemporal dementia 
with parkinsonism linked to chromosome 17. Tau-negative conditions are characterized 
by undetectable insoluble tau, be they ubiquitin-positive or negative. Among these, 
frontotemporal dementia with motor neuron disease is associated to ubiquitin-positive 
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but tau-negative inclusions, while ubiquitin-negative inclusions seem to correspond to 
frontotemporal dementia lacking distinctive histopathology (McKhann et al, 2001). 
 
 
2.3 Epidemiology of FTD 
 
As a dementia with presenile onset and rather short duration, the prevalence on FTD is 
low in senile patients and higher in younger ones. In particular, a proportion of 15% of 
dementia cases has been found in two studies (Ratnavalli et al., 2002), while a 
proportion of 3% was identified in a population-based sample of 85 year olds (Gislason 
et al., 2003). Although some authors state that men and women can be equally affected 
by FTD (Snowden et al., 2002, Binetti et al, 2002), numerous studies report a higher 
percentage of men in their FTD samples (Ratnavalli et al., 2002). The mean duration is 
8 years, but the variability is extremely wide (2 to 20) (Snowden et al., 2002). 
 
 
2.4 Histopathology of FTD 
 
In the history of the characterization of FTD there has been a tendency to refer to it as 
Pick’s disease, due to the initial descriptions. Indeed, Pick bodies can be detected at 
pathological examination, but the pathological findings in subjects with the clinical 
symptoms of FTD can vary considerably. Focusing on results obtained with 
immunohistochemical staining with antibodies to tau, ubiquitin and αB crystallin, a 
number of different diseases can be separated, all causing the typical symptoms of FTD. 
For this reason, the most recent approach has consisted of including a variety of 
pathological characteristics as possible findings in FTD. 
The diagnosis of FTD lacking distinctive histopathology is generally confirmed when 
no intraneuronal inclusions are found with antisera to tau and ubiquitin, and when there 
is microvacuolation of cortical layer II in the frontal and anterior temporal cortices, 
which can be severe and transcortical, with variable degrees of subcortical gliosis. Mild 
or moderate atrophy can be accompanied by a variable number of αB crystallin-
immunoreactive swollen cortical neurons (Jackson and Lowe, 1996). Enlarged criteria, 
including different types of histological findings associated with FTD symptoms, can 
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also include cytoplasmatic inclusions in small nonpyramidal neurons in the upper 
cortical level of the frontal and temporal cortex, and in the amygdala, basal ganglia and 
brain stem. Neurofibrillary tangles can also be observed, as can ubiquitin-positive 
inclusions, the latter generally when FTD is associated with motor neuron disease 
(McKahnn et al., 2001). 
Recently, a neuropathological characterization (Mott et al., 2005) tried to validate the 
guidelines elaborated by the Bethesda Work Group, by investigating 21 FTD patients 
with traditional histochemical stains and tau and ubiquitin tests. The Authors have 
divided the FTD cases into six neuropathologic categories by traditional examination 
(Pick disease, corticobasal degeneration, dementia lacking distinctive histopathology, 
progressive supranuclear palsy, frontotemporal lobar degeneration with motor neuron 
disease or motor neuron disease-type inclusions, and neurofibrillary tangle dementia). 
All cases were then independently evaluated by the insoluble tau isoform pattern 
indicated by the last criteria (McKhann et al., 2001), including 3R, 4R, 3R/4R, and no 
insoluble tau: the patterns strongly correlated with the independently derived 
histopathologic diagnoses, with cases characterized by predominant 3R corresponding 
to Pick’s disease, cases with predominant 4R tau corresponding to either corticobasal 
degeneration or progressive supranuclear palsy, and cases with 3R/4R being either a 
combination of Pick’s and AD, or frontotemporal lobar degeneration with motor neuron 
disease or motor neuron disease-type inclusions. Insoluble tau was reduced in dementia 
lacking distinctive histopathology and in frontotemporal lobar degeneration with motor 
neuron disease. Observations about ApoE in these cases showed that the ε4 allele is 
overrepresented in Pick’s Disease and in dementia lacking distinctive histopathology. 
This whole study provided a first validation of the general framework proposed by the 
Bethesda group (McKhann et al., 2001). 
 
 
2.5 FTD and genetics 
 
FTD was first linked to chromosome 17 in 1994, when the locus of the “disinhibition-
dementia-parkinsonism-amyotrophy complex” was identified on chromosome 17q21-22 
(Wilhelmsen et al., 1994). Subsequently, mutations of the tau protein, encoded on 
chromosome 17, have been repeatedly demonstrated in patients belonging to the wide 
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family of frontotemporal dementia. These mutations involve both exons and introns 
around the microtubule binding region of tau. Nevertheless, only a small percentage of 
patients with FTD carries tau mutations, nonetheless most of them have abnormal 
accumulation of tau protein. At the same time, patients with very similar mutations are 
affected by very different frontotemporal syndromes (Rosen et al., 2000).  
Contrary to what happens in AD, the APOE-ε4 allele does not represent a risk factor for 
frontotemporal dementia, although it is over-represented in a number of samples. Based 
on the recent validation of the last criteria for diagnosis of FTD, the ε4 allele is 
overrepresented in Pick’s Disease and in dementia lacking distinctive histopathology 
(Mott et al., 2005). 
The motor-neuron disease, when linked to frontotemporal dementia, has also been 
described to correspond to a genetic locus on human chromosome 9q21-q22. 
 
 
2.6 Clinical differential diagnosis from AD 
 
Although AD and FTD have definitely different clinical phenotypes, FTD can be, and 
often actually is misdiagnosed as AD. The opposite may also happen, particularly when 
“frontal” symptoms occur. The frontal lobes had the most recent development both 
phylogenetically and ontogenetically, and require high metabolic effort, as well as 
integrity of connected structures, to carry out their functions. Therefore, frontal 
symptoms can be frequently observed in dementia patients other than FTD. Moreover, a 
frontal variant AD has been described (Johnson et al., 1999), that pathologic 
examination detected to be characterized by a higher concentration of neurofibrillary 
tangles in the frontal lobes compared to typical AD brains (senile plaques pathology in 
the frontal and entorhinal regions did not differ between the two groups). Therefore, 
when the currently adopted clinical criteria for diagnosing AD (McKhann et al, 1984) 
were tested as to their accuracy in differentiating AD from FTD, specificity to FTD was 
found to be very poor (0.23), notwithstanding a high sensitivity in detecting AD (0.93) 
(Varma et al., 1999). This requires to consider FTD criteria together with AD ones in 
evaluating a new dementia patient. The criteria elaborated in 1984 (Neary et al., 1998) 
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correctly classified 93% of patients with FTD and 97% of AD in a validation study 
(Rosen et al., 2002).  
Other characteristics are of help in the clinical evaluation of people with dementia. 
Patients with FTD are usually younger than patients with AD (Neary et al., 1996), and 
they are unaware of the early change in their personalities and inappropriate behavior. 
In contrast, AD patients are aware of the changes and maybe able to hide them, but 
become understandably depressed and upset due to this awareness of their condition. 
The stereotypy of language and behavior, ranging from apathy to disinhibition, is quite 
different from the typical AD patients, who are still able to interact appropriately in 
social contexts. 
From a neuropsychological point of view, it has been observed that the first symptoms 
differentially characterized not only FTD and AD, but also FTD with mainly right, left 
or bilateral atrophy (Lindau et al., 2000). In detail, memory loss first presented in AD , 
while disinhibition characterized right-sided FTD, and language dysfunction left-sided 
FTD. Executive function was most frequent in bilateral FTD. 
Anyway, although a number of tests are typically differentially impaired in the two 
conditions, the reliability of test performances has been repeatedly debated, even when 
these were rather typical for the two dementias (Grossi et al., 2002).  
For this reason, biological markers are being sought in order to help in the differential 
diagnosis. Biological markers can be detected in vivo via cerebrospinal fluid (CSF) 
analysis extracted by lumbar puncture or, alternatively, via visualization of cerebral 
structures or function with neuroimaging techniques. CSF analysis showed that, 
contrary to AD, presenting with reduced Aβ and increased total tau levels compared to 
controls, FTD patients exhibit increased Aβ, and variably described levels of tau, which 
is generally higher than observed in controls, but lower than in AD patients (Rosso et 
al., 2005).  
 
 
2.7 Clinical manifestations of FTD  
 
FTD has been constantly described with the same peculiar set of clinical characteristics 
mainly involving altered personality, behavior and language. Nonetheless, the diagnosis 
19  
of this condition is still challenging, due to the considerable overlap of its symptoms 
with those of AD (Varma et al., 1999). 
Heterogeneity in the combination of symptoms in different geographic areas can be 
observed. For example, in the Finnish variant of FTD (Nasu-Hakola disease or 
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) 
systemic bone cysts are known to be associated to the ordinary set of symptoms of 
frontotemporal dementia (Hakola et al., 1974). The combination of neuropsychiatric 
symptoms and bone cysts is unique to this disease, that is also described in Japan and 
Italy. The molecular defect has been identified in loss-of-function mutations in the 
TYROBP gene in Finnish and Japanese patients (Paloneva et al., 2000), and in the 
TREM2 gene in other families of different ethnic origins (Soragna et al., 2003). 
 
 
2.7.1 Physical symptoms 
 
Primitive reflexes, incontinence and altered blood pressure values are also observed. 
Although some observations describe lower blood pressure as a common symptom in 
degenerative dementias (Passant et al., 1996), this is commonly reported as a defining 
symptom in FTD (Neary et al., 1998).  
Together with altered dietary behavior and the Klüver-Bucy-like symptoms, they seem 
to indicate the involvement of rather deep or ancient structures, in contrast with the 
ordinary description of cortical lobar atrophy.  
Akinesia and other extrapyramidal symptoms are likely to occur in FTD and help 
distinguish it from other degenerative disorders (Rosen et al., 2002).  
Although amyotrophic lateral sclerosis (ALS) can be independently associated to FTD, 
a high prevalence of this condition (up to 38%) (Lipton et al., 2004) is registered. 
Recent studies have attempted to identify the basis for this concurrence (Prudlo et al., 
2004, Lipton et al., 2004), which seems more striking after the recent publication of 
“frontal” symptoms in patients with ALS (Lomen-Hoerth, 2004). 
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2.7.2 Language 
 
Language involvement is observed even in the early stages of disease, and can end in 
mutism at later stages. Even in patients that seem to have preservation of language, a 
specific problem related to verb processing has been described (Hodges and Miller, 
2001) 
Linguistic functions can be considered to be as badly disrupted as other kinds of 
behaviors. For example, it can be stereotyped and repetitive resembling the frontal 
symptoms of perseveration and of stereotyped behavior. Furthermore, as with the 
presence of other core features such as emotional blunting, it can be aspontaneous and 
scarce being due to a lack of motivation (Neary et al., 1998).  
Linguistic functions are severely involved in the other two types of frontotemporal lobar 
degeneration (semantic dementia and progressive nonfluent aphasia) where language 
impairment is the main characteristic of the disease.  
 
 
2.7.3 Behavioral symptoms 
 
Cognitive functions are clearly impaired in FTD, but neuropsychological tests often 
produce contradictory results even when the evaluated functions are those typically 
impaired in this kind of dementia. For example, an attempt to discriminate AD from 
FTD might involve tests of memory function and executive functions, which are 
thought to be differentially impaired in the two conditions, but the neuropsychological 
patterns described in literature are not so clear-cut, nor consistent across different 
studies. This neuropsychological inconsistence confirmed the belief that FTD is 
primarily a neurobehavioral syndrome (Perry and Miller, 2001), where abnormalities 
become evident especially in dealing with one’s own environment, rather than in 
isolated and easy measurable cognitive functions. 
If we wish to classify and define the abnormal behavior of FTD patients, their problems 
fall into a wide variety of alterations, from physiological self-regulation to interpersonal 
relationships. Altered functions also exhibit a wide range of manifestations. For 
example, altered food intake range from unbalanced dietary preferences such as 
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excessive intake of carbohydrates, to consumption of non edible objects. Similarly, 
improper social behavior might range from excessive jocularity to apathetic behavior. 
As some of these symptoms might overlap with other kinds of dementia such as AD, 
some researchers have tried to define which of them best discriminate between the two 
conditions. In 2000 Bozeat et al showed that stereotypic and altered eating behavior, 
together with loss of social awareness, could reliably differentiate FTD from AD, and 
that this pattern of symptoms was quite similar to that of semantic dementia. This study 
suggested that a common network might underlie both syndromes and, above all, that 
FTD might consist of a neuropsychiatric syndrome due to disruption of a specific 
network, putatively the anterior limbic system, connecting emotional structures like the 
amygdala to the ventral frontal cortex, with the function of guiding adaptive behavior. 
Subsequent studies investigating the nature of behavioral abnormality in these patients 
consistently added to the evidence of disruption of this kind of self-regulating network 
(see Study V). 
In this evolution of neurobehavioral studies of these patients, therefore, there has been a 
shift of attention from single behavioral problems (change in personality, emotional 
unconcern, disinhibition, etc.) to more basic and general behavioral problems (i.e. 
disruption of self-regulating and adaptive behavior) that better describe the disruption of 
specific brain networks, and more economically gather apparently heterogenic 
symptoms into wider and more informative diagnostic categories. 
In the following sections, the typical symptoms of FTD will be reviewed in a 
“traditional” way, and will be finally gathered into the more recent interpretation of the 
syndrome. 
 
 
2.7.4 Change of personality 
 
The clinical picture of FTD is characterized by early changes in personality. This kind 
of symptom is particularly strange as well as vaguely defined. It refers to altered 
personal and social conduct, and behavioral changes mainly consisting of disinhibition, 
jocularity, irritability, euphoria, emotional unconcern or apathy. Personality alterations 
include changes in taste, for example in music listening (Geroldi et al., 2000), as well as 
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the birth of new artistic abilities (Miller et al., 2000). Profound alterations of the self 
such as change in political, social and religious values have been thought to be 
associated to the asymmetric involvement of the non-dominant hemisphere (Miller et 
al., 2001).  
 
 
2.7.5 Emotional unconcern 
 
FTD patients are apparently unaware of their social context showing inappropriate 
behavior and emotional unconcern. Apathy is a frequently observed feature in these 
patients, but it should not be considered as a depression trait (Levy et al., 1998). While 
depression can be a normal emotional reaction to a negative condition, apathy rather 
refers to some sort of disconnection from motivational sources, causing lack of 
initiation and loss of motivation or drive. The behavior of these patients resembles that 
of a passive organism automatically and stereotypically reacting to stimulation rather 
than actively searching for relief or seeking a solution to its own problems. 
Paradoxically, in the same condition, disinhibition is found, which seems to be a 
diametrically opposite symptom, but this in fact points to the disruption of a system 
regulating emotional behavior.  
This form of emotional unconcern was recently characterized in the Theory of Mind 
functions (Lough et al., 2001; Gregory et al., 2002), which means that these patients are 
unable to empathically participate to another one’s situation and to behave 
appropriately. Insight into one’s own situation and the related appropriate behavior are 
equally lacking.  
 
 
2.7.6 Other cognitive functions 
 
Features such as obsessive-compulsive symptoms can be related to frontal dysfunction. 
Other behavioral features (stereotypy, perseverative behavior, etc.) denote in fact a 
marked frontal involvement, but some frontal functions may be relatively intact during 
neuropsychological testing (Rahman et al., 1999; Lough et al., 2001) despite the marked 
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alterations in behavior, this being the case in some non demented frontal patients 
(Damasio, 1995). Rahman and colleagues (1999) argued that the heterogeneity of the 
frontal cortex and of its connections and functions accounts for the particular patterns of 
frontal impairment of FTD, and this is why many typically frontal tests, such as the 
Wisconsin Card Sorting Test, the Tower of London or working memory tests can be 
unimpaired in mild FTD patients, who show instead altered behavior in decision making 
tasks. In decision making tasks (Rogers et al., 1999) and other tests sensitive to 
orbitofrontal function, such as the gambling task (Bechara et al., 1997), FTD patients 
are able to make accurate probability judgments, but cannot adjust their bets 
appropriately, appearing as greater risk-takers than controls, as well as other “frontal” 
patients (Bechara et al., 1994; Bechara et al., 1998). This behavior has been interpreted 
as an inability to anticipate future outcomes, but the “anticipation” should be considered 
as an “emotional” anticipation, driving the patient to modify his/her behavior 
accordingly, rather than a pure “cognitive” prevision of possible outcomes (Damasio, 
1995). This kind of impairment indicates that neurological involvement should be 
expected located in the ventromedial rather than dorsolateral frontal cortex. 
Memory and orientation are relatively preserved compared to AD, but still abnormal, 
and those changes increase the difficulties in the differential diagnosis. Some tests very 
typically failed by AD patients, such as those of episodic memory, especially for the 
location of objects in space (Swainson et al., 2001), are performed well by FTD 
patients, and are therefore rather useful in making a clinical diagnosis (Lee et al., 2003). 
FTD patients show impairment in the reversal learning stages, which has been 
interpreted by some authors as being due to an involvement of the ventral striatum, data 
supported by experimental work on primates (Divac et al, 1967), as well as from 
cytoarchitectonic connections (Williams et al., 1993).  
The most recent studies in the field of social cognition showed that the Theory of Mind 
is impaired in FTD patients (Hodges and Miller, 2001) and that it dissociates from 
frontal executive function (Lough et al, 2001). One aspect linked to the Theory of Mind 
is the ability to recognize emotion from facial expression. The first study assessing this 
function in FTD appeared in 1999, and compared these patients to AD subjects and 
healthy controls (Lavenu et al., 1999). While all subjects could correctly distinguish 
neutral faces from those expressing emotions, FTD patients had a poorer ability than 
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AD patients in naming anger, sadness and disgust. Both FTD and AD patients had 
worse performance than controls in naming fear and contempt, but the more 
circumscribed impairment of AD points to involvement of different systems in these 
patients.  
 
 
2.7.7 Recent interpretations of clinical data about FTD 
 
The evidence that FTD patients might show unexpectedly little impairment in frontal 
test as well as the confusing overlap in cognitive performance with AD demanded a 
move away from strategies for the interpretation of the disease based on single function 
impairment to a more general system impairment. This happened thanks to a variety of 
heterogenic evidence, ranging from the recently explored behavioral alterations of 
neurological frontal patients, to the developing of the new field of social cognition. 
Indeed, critical observations in the field of cognition recently shifted the focus of 
attention of researchers from the “cognitive” to the “emotional” level. Actually, as 
effectively pointed out by Damasio (Damasio, 1998) in the course of numerous 
contributions, “emotion” has long been neglected in the cognitive neurosciences, and 
misleadingly considered as being opposite to the typically “cognitive” aspects of brain 
functioning. Instead, emotion is a kind of cognitive information that allows the 
organism to adapt to its environments according to different survival needs. What 
characterizes emotion, giving it the features that make it appear so different from 
cognition, is that the drives derived from it can scarcely be controlled and pushily guide 
behavior despite one’s own “will”. What was not considered until recent times was that 
this “pushy” feature of emotion is what guarantees survival to the organism, as emotion 
guides behavior relating to survival issues that should not be disregarded.  
The second step in the evolution of knowledge in this field consisted in the concept that 
this newly recognized function, i.e. the guiding behavior in the direction of 
“emotionally” marked physiological goals, is mediated by the frontal lobes, whose 
connections to the limbic regions of the brain are particularly rich. The frontal lobes are 
the optimal region to carry out this sort of functions, for many reasons, e.g. a) they have 
a complete representation of the entire organism and b) they are involved in the control 
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of behavior, and can therefore provide optimal satisfaction to the organism’s needs by 
behaving in a way finalized to modify the environment and answer to that need 
(Goldberg 2002). In these terms, it is clear that “emotion”, rather than being an 
irrational function of the brain, is a very rational aspect, aimed at guaranteeing optimal 
survival of the individual in its environment (Damasio, 1995). 
When one considers human beings, the social context is a particularly important part of 
the environment to which the individual has to adapt, and that the individual can utilize 
to reach personal aims. For this reason, particularly in primates another newly 
recognized function has evolved, consisting of the concept of “social competence”. This 
includes understanding and prevision of the state of mind in other individuals of the 
species, recognizing of cues directly indicating their internal conditions (like facial 
expression of emotions) and empathy. Empathy is the force that guarantees social 
cohesion, and a biological basis for empathy has been recently recognized in the so-
called mirror-neurons (Rizzolatti et al., 1999). 
All of these recent approaches are being intensely investigated by neurobiologists, that 
are progressively more able to connect and relate them to human brain structure 
(Adolphs 2001). It is increasingly clear that a great number of pathologic conditions are 
characterized by impairment in different components of this complex “adaptive” system 
and that these impairments might be central to the disease, as seems to be the case in 
autism, or might be a secondary component, caused by other major damage (such as the 
impaired recognition of some emotions in Huntington disease). The set of symptoms 
described in the previous sections point to a new explanation of FTD, considering this 
syndrome to represent the disruption of such adaptive system. This interpretation fits the 
evidence of the inconsistent results obtained in traditional “cognitive” tests, the failure 
in tests of social competence and the well known disruption of personal and social 
conduct. The search for a biological marker, previously sought primarily in order to 
discriminate the condition from other kinds of dementias, may now be guided by this 
more unitary interpretation of the disease, clearly pointing to the involvement of definite 
systems (Adolphs, 2001). 
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2.7.8 Studies of bizarre symptoms in FTD  
 
The set of symptoms described in the last paragraphs point to the involvement of a set 
of structures implicated in functions that best distinguish the human being: emotional 
understanding and taking part in social roles, maintaining proper conduct, finalizing 
behaviour to convenient goals. People lacking functions of this kind typically encounter 
difficulties when they are involved in activities or interpersonal relationships, which is 
particularly troublesome for any attempt at rehabilitative treatment. The strange 
condition and conduct of these patients, who are usually unaware of their illness and 
presenting a wide range of symptoms from simple apathy to inappropriate positive –
even euphoric- moods, inevitably gave rise to a number of particularly original studies 
addressing these peculiar traits. As bizarre was the content of the visual hallucinations 
of a young euphoric patient diagnosed as FTD (Reischle et al., 2003), equally bizarre 
are other described traits such as an alteration in the humanness, inducing FTD patients 
with predominant right atrophy to judge as “human” the morphed or masked faces not 
recognized as “human” by other FTD patients with left involvement or controls 
(Mendez et al., 2004). Similarly, other authors measured agreeableness of FTD patients 
according to the NEO-Five Factor Inventory score obtained by care-givers’ evaluation 
of the patient, and found it to be negatively correlated to left and positively correlated to 
right orbitofrontal volume (Rankin et al., 2004). The peculiarity of such behaviors and 
findings more than once induced researchers to wonder whether FTD is a dementing 
disorder uniquely determining loss of function, or whether some positive aspects and 
functions could actually be gained. In one of these studies, a lawyer who previously 
considered pop music to be “mere noise” actively sought out tapes of a popular Italian 
pop group, which he then played over and over at full volume for most of the duration 
of his disease, while a grandmother shared with her 11-year-old granddaughter a strange 
enthusiasm for pop music (Geroldi et al, 2000). Similarly, several studies from a group 
long describing FTD reported acquisition of artistic drive from the visual to the musical 
field, and describe this condition as often being associated to anterior temporal atrophy 
(Miller et al., 1998; 2000; 2004). Left hemisphere damage is also thought to be 
responsible for the release of supposedly “right” artistic drive. Similar data are actually 
common to other pathological conditions such as autism (Munoz-Yunta et al., 2003) or 
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epilepsy with frontal focus (Finkelstein et al., 1991). Indeed such studies provide an 
unexpected opportunity to explore creativity and artistic talent as complex and yet 
mysterious human abilities. 
 
 
2.8 Brain morphology in FTD 
 
2.8.1 Atrophic structures in FTD 
 
Brain morphology, as investigated at structural neuroimaging studies, is constantly 
characterized in FTD patients by atrophy of the anterior section of the temporal lobes 
and of the frontal lobes, which is paralleled by decreased perfusion detected at 
functional imaging (McKhann et al., 2001). This pattern of anomalies is typical and 
distinctive of FTD, since involvement of the parietal lobe usually corresponds to AD 
pathology. In some patients atrophy of deep structures, like the corpus striatum and the 
amygdala, is observed (the Lund and Manchester group, 1994). 
As to frontal morphology, atrophy has been observed in diverse sectors of this lobe: 
dorsolateral, orbitofrontal, ventromedial and anterior cingulate (Rosen et al., 2002). The 
anterior temporal atrophy mainly characterized SD in a direct comparison of the two 
syndromes (Rosen et al., 2002), but can be found in FTD as well. 
The observation of amygdaloid and striatal atrophy comes from pathological studies 
(Filley et al, 1994).  
 
 
2.8.2 Different involvement of the two hemispheres 
 
One of the most typical features of FTD is asymmetry, which is evident at both the 
clinical and biological levels. The involvement of language, that can be affected early 
and disproportionately (Neary et al., 1998), indicates greater involvement of the left 
hemisphere. In other cases, behavioral disturbances predominate, which may indicate 
greater right hemisphere involvement (Mychack et al., 2001). At the biological level, 
strikingly asymmetric hypometabolism and atrophy, as detected with in vivo imaging 
methods, have been repeatedly described, as well as an asymmetric distribution of 
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lesions on pathological studies (Miller and Gearhart, 1999; Filley et al., 1994). 
However, asymmetry may also be absent. Miller and Gearhart analyzed 15 FTD patients 
with single photon emission tomography (SPET) and magnetic resonance imaging 
(MRI), and observed symmetric hypoperfusion in 3, and symmetric atrophy in 7 of the 
subjects (Miller and Gearhart, 1999). Filley and colleagues reported symmetric 
involvement in 2 of 4 FTD patients at pathological evaluation (Filley et al., 1994). 
 
 
2.9 Therapies for FTD 
 
Insight into the neurochemical involvement on FTD is still in its infancy, and there are 
few studies on this aspect. Observations that cholinergic activity are decreased in the 
nucleus basalis of Meynert of both AD and FTD have led to attempts to use 
acetylcholinesterase inhibitors in FTD, but this kind of treatment does not have any 
scientific evidence of efficacy in this disease (Perry and Miller 2001). 
Clinical observations lead to the proposal that the serotonergic system could be 
involved. Weight gain, altered food preferences and obsessive compulsive symptoms 
may be due to frontal and subcortical serotonin loss (Miller et al., 1995). Indeed, 
serotonergic receptor abnormalities have been observed at autopsy in FTD patients 
(Sparks et al., 1991). Neuropsychological and neuropharmacological studies seem to 
confirm the possibility of a specific serotonergic involvement: increases in deliberation 
times similar to those observed in FTD in decision making tasks were in fact observed 
in normal subjects with low levels of 5-HT induced by consumption of a low tryptophan 
drink (Rogers et al, 1999). These subjects also showed altered performance in 
performing a simple reversal rule, thus resembling FTD performance in these kinds of 
tasks (Park et al., 1994).  
Selective serotonin reuptake inhibitors (SSRI) are currently being used for treatment of 
FTD symptoms (Swartz et al., 1997), in particular, against impulsive behavior 
(Coccaro, 1989), aberrant dietary (Yager, 1988) and obsessive-compulsive behavior 
(Hollander, 1996). Initial results indicated some benefits, but more systematic studies 
failed to confirm this proposal (Deakin et al, 2004). Thus, data on efficacy of this 
treatment must be considered as controversial (Deakin et al., 2004). 
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2.10 Imaging diagnostic tools in FTD  
 
Structural and functional tools are used in clinical diagnosis with the aims of excluding 
nondegenerative causes of cognitive impairment and of helping in the diagnosis, in 
particular the differential diagnosis between different kinds of dementias (DeCarli, 
2001). The finding of a reduced volume is a strong index of grey matter degeneration at 
structural examination, but initial stages may not present such alterations. Functional 
findings, usually indicating frontal hypoperfusion (Diehl et al., 2004), may be 
ambiguous, since they can overlap with other conditions (Soderstrom et al., 2002) but 
can help diagnosis in very initial stages of disease, when structural imaging is still 
normal, as a confirmation of a clinical diagnosis already based on the behavior and 
symptoms. For these reasons, some clinicians rely more on functional findings, while 
others seek the more concrete data of structural imaging. 
 
 
2.10.1 The development of the most frequently used structural imaging tools  
 
Imaging studies have evolved very rapidly in recent years, particularly as a consequence 
of the growing precision and complexity of the software used in processing the source 
images. Before the late ‘70s there was no mention about volumetric measures on brain 
imaging scans of any kind. However, in 1975, the first report appeared highlighting the 
utility of CT (computerized tomography) scans in separating dementia cases from 
possibly reversible causes of cognitive impairment (Fox et al., 1975). In 1985 tracing of 
regions of interest and computation of their volume was used in order to define normal 
morphology in CT scans (Thompson et al., 1985). In the same years, the first evidence 
of clinical utility of MR imaging for cerebral disease was described (Huk et al., 1984). 
Pioneer studies using automated procedures to extract volumes from imaging scans 
emerged in the ‘80s (Bloch et al., 1986), and at the end of that decade a volumetric MR 
study of the temporal lobe in normal subjects was published (Jack et al., 1988). In 1989, 
the first volumetric rendering for MR images was developed, that could segment brain 
tissue, and display it on three-dimensional views of brain structures as well as modern 
software do (Rusinek et al., 1989). With aid of a phantom, the accuracy of 
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measurements was repeatedly tested, and in 1990 the first group of AD patients was 
assessed (Ashtary et al, 1990). Immediately after that, a stereotaxic method for MR 
images was devised to simulate surgical procedures beforehand, allowing positioning 
with a precision of 1 millimeter (Derosier et al., 1991), and in 1994 the Talairach space 
was used to try find an unambiguous membership of each 3D point to a brain structure 
(Collins et al., 1994). During those years, researchers handled the problem of warping 
the individual brains in order to fit an ideal model, so that comparisons between 
different individuals could be carried out by limiting individual variance (Mazziotta et 
al., 1991). When the first voxel-based techniques were developed (Wright et al., 1995), 
software was already available capable of generating parametric images representing the 
distribution of different elements in histological section (Albe et al., 1985) and this 
could be used in comparing MRI scans. At present, the statistic parametric mapping 
(SPM) is widely used to compare volumes in groups of individuals. A recent advance in 
this approach has permitted non parametric comparison based on Bayesian a priory 
probability (SPM2).  
Different characteristics of MR imaging can be used for rather heterogenic aims, from 
visualization of function –contrary to the typical use of this technique- (Belliveau et al., 
1991) to identification of the connection fibers (Wolff and Balaban, 1989), depending 
on which physical property of the brain matter one wishes to evaluate. While this last 
technique has never been used in FTD studies, an activation study using functional MRI 
recently demonstrated reduced frontal activation in these patients (Rombouts et al., 
2003). 
 
 
2.10.2 Structural MRI studies in FTD 
 
Regional atrophy detected with magnetic resonance imaging (MRI) can be considered 
as a biological marker of degenerative diseases. In AD, accurate volumetric 
measurements have indicated that atrophy in the medial temporal lobe can be detected 
early in the disease course and this has been proposed as being a diagnostic indicator 
(Jack et al., 1992). On the contrary, atrophy in the frontal and temporal lobes in FTD is 
a more controversial diagnostic marker for many reasons. First, different studies have 
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provided contrasting results. Some have found frontal and asymmetrical atrophy in FTD 
patients (Miller et al., 1999; Duara et al., 1999) while others could not find any evidence 
for frontal and temporal atrophy in small series of typical and very early FTD patients 
(Hokoishi et al., 1999; Gregory et al., 1999). Second, most studies either did not 
compare atrophy in FTD patients to that of controls or other types of dementia (Miller et 
al., 1999; Gregory et al., 1999), or else gave only visual subjective ratings of the extent 
of atrophy (Miller et al., 1999; Gregory et al., 1999; Larsson et al., 2000). Unexpected 
results derived from the comparison of very typical ROIs that might separate different 
conditions such as AD and FTD: the volumes of hippocampus and entorhinal cortex in 
AD and FTD were measured, but these volumes had good discriminative power only for 
AD versus controls (Frisoni et al., 1999). The failure of this strategy, that was aimed at 
measuring structures considered to be severely involved in AD and not crucially 
damaged in FTD, suggested that a pattern of atrophy in different regions, rather than the 
amount of atrophy in a single region, could be more informative in the differential 
diagnostic process. The first authors who used the “pattern” approach to characterize 
different diseases successfully separated dementia with Lewy body (DLB), AD, and 
vascular dementia (Barber et al., 2000), and postmortem volumes of progressive 
supranuclear palsy (PSP), Parkinson's disease (PD) and DLB (Cordato et al., 2000). In 
the first study, MRI scans were quantitatively compared indicating a different 
distribution of atrophy through the ventricles, frontal and temporal lobes, hippocampus 
and amygdala. The relative preservation of frontal lobes was constant in the three 
diagnostic conditions, which were separated mainly by the medial temporal volumes, 
that showed severe atrophy in AD, a tendency towards atrophy in vascular disease and 
very mild involvement in dementia with Lewy Bodies. In the second study, postmortem 
measures were taken from whole gray and white matter, lobar cortices, medial temporal 
structures, basal ganglia and thalamus, and indicated very severe involvement of globus 
pallidus and amygdala in PSP, and, to a lesser degree, of frontal and parietal cortices. 
Together with the finding of relative preservation of hippocampus, the whole pattern 
helped distinguish PSP from DLB, where this structure was involved, while the globus 
pallidus was not affected. The whole pattern was, again, distinct in PD, where only the 
medial temporal structures, and particularly the amygdala, revealed significant atrophy 
(Table 1). 
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Table 1. Brain volumes in different kinds of dementia. 
Volumes at 
MRI 
DLB AD VaD  Volumes at autopsy PSP PD DLB 
Whole brain n.s ↓ ↓  Whole gray matter  ↓ n.s. n.s. 
Ventricles ↑ ↑ ↑  Internal globus 
pallidus 
↓↓ n.s. n.s. 
Frontal 
cortex 
n.s n.s n.s  Frontal cortex ↓↓ n.s. ↓↓ 
Temporal 
cortex 
↓ ↓ ↓  Parietal cortex ↓ n.s. n.s. 
Hippocampus ↓ ↓↓ ↓  Hippocampus ↓ n.s. ↓↓ 
Amygdala n.s ↓↓ ↓  Amygdala ↓↓ ↓↓ ↓ 
 
Modified from Barber et al., 2000 and from Cordato et al., 2000 
 
 
These works suggested that the pattern of atrophy might be more informative and 
discriminative between the different diseases and be superior to the single region 
approach, since atrophy of single regions may overlap in the different diagnostic 
groups. 
Some authors have studied the pattern of atrophy in FTD patients but have not 
investigated its discriminative power from other types of dementia (Fukui and Kertesz, 
2000; Kitagaki et al., 1998) and others claimed that they could not obtain a good 
discriminative power (Frisoni et al., 1999). MRI-based measures of lobar volumes of 
FTD, primary progressive aphasia and AD patients were compared, and the right and 
left frontal volumes provided a correct classification of 93% of FTD and primary 
progressive aphasia patients, but specificity versus AD patients was not reported (Fukui 
and Kertesz, 2000). 
33  
Table 2: MR Imaging morphometric studies on FTD. 
Author Year of 
publication 
Structure of interest Method of analysis  Atrophic structures Other studied characteristics 
Williams et al. 2005 whole GM VBM  anterior temporal lobes 
subcallosal gyrus,dorso-mesial 
PFC,paracingulate region 
Semantic knowledge  
Aberrant behavior 
Rankin et al. 2004 OFC 
 amygdala 
ROI tracing  (correlation study) Agreeableness  
McMillan et al.  2004 Whole GM VBM  Left temporal lobe 
 
Confrontation naming 
Liu et al. 2004 PFC, VMFC, anterior 
temporal lobe, amygdala 
ROI tracing   PFC, VMFC Aberrant behavior 
Gee et al 2003 Whole GM VBM  Left temporal lobe 
Left frontal lobe 
Naming  
Simons et al. 2002 hippocampus ROI tracing  hippocampus Recollection based memory 
Rosen et al. 2002b PFC, OFC, ATC, amygdala ROI tracing  ATC, amygdala, OFC Emotion comprehension 
Rosen et al. 2002a Whole GM VBM  Anterior Cingulate, OFC, anterior 
insula 
- 
Chan et al. 2001 Whole GM BBSI  PFC Rate of atrophy 
Fukui et al. 2000 Lobes and basal ganglia Semiautomated ROI 
segmentation 
 Frontal lobe Neuropsychological functions   
Laakso et al. 2000 Hippocampus, entorhinal 
cortex 
Manual ROI tacing  Anterior hippocampus, entorhinal 
cortex 
Topographic distribution of 
atrophy within the atrophic 
structure 
Frisoni et al. 1999 Hippocampus and 
entorhinal cortex 
Manual ROI tracing  Hippocampus, entorhinal cortex - 
Kitagaki et al. 1998 Whole cortical surface Automated ROI 
segmentation 
 PFC, AT, and whole cortex Asymmetry of atrophy 
Kaufer et al. 1997 Corpus callosum and 
pericallosum regions 
Semiautomated ROI 
tracing 
 Anterior corpus callosum MMSE 
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Overall, imaging studies on FTD have the main gap of focusing attention on single 
regions of interest that turn out to be of little help in discriminative diagnosis and 
pathogenesis comprehension, with few exceptions. These exceptions, on the other hand, 
did not investigate the discriminative power of such findings in the differential 
diagnosis with other kinds of dementias, mainly AD. As well, the comprehension of the 
pathogenesis of FTD and the origin of its symptoms is far from exhaustive. Finalized 
researches seeking the origins of individual symptoms, or of the whole syndrome, are 
lacking in the literature.  
As well, other minor aspects were disregarded or corresponded to contrasting results. 
For example, the distribution of atrophy among the right and left hemispheres was 
variably described in different studies, that analyzed different samples or used different 
techniques (i.e. volumes or perfusion). Another aspect is the representation of the ε4 
allele of APOE: among the contrasting results about the allelic frequency, studies 
investigating its role in the clinical or morphological expression of the disease are 
lacking.  
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3. AIMS OF THE STUDY 
 
This study was undertaken when no voxel-based morphometry (VBM) studies on FTD 
were available. The few morphometric works had been carried out with manual or, at 
best, semiautomated techniques. Regions of interest were those in common with AD, 
chosen in order to try discriminate FTD from this condition. Unfortunately, a similar, 
although less severe, distribution of atrophy in these regions is present also in FTD, 
preventing one from making an accurate discrimination of the different dementias based 
on these biological markers. Studies that considered regions outside the medial 
temporal, (i.e. the corpus callosum, or the hemispheric surface) only provided 
confirmation of the “anterior” atrophy already known to characterize FTD (Table 2). 
Given the relatively paucity of quantitative data on structural imaging in FTD, the poor 
discriminative power of these data in the separation of FTD and AD, and the poverty of 
comprehension of the pathogenesis of the disease, this study was designed with the aim 
of deepening the knowledge of quantitative brain morphology with the first purpose of 
improving differential diagnosis with AD and other forms of degenerative dementias 
(study I). As noted above, the failure of studies examining single, although highly 
characterizing, regions of interest motivated us to change the strategy, and to adopt a 
“pattern” approach similar to those described in Study I, first used by Barber and 
Cordato. This kind of approach is aimed at finding more informative and discriminative 
biological markers, and, eventually, at tracking networks that could account for the 
complex and contradictory clinical picture of FTD. 
Indeed, in addition to this diagnostic aim, a deeper insight into the neurological 
mechanisms underlying symptoms and neuropathology was sought. The 
counterintuitive data about behavioral symptoms motivated us to investigate the 
pathogenesis of the disease starting from the examination of key structures, for example 
the amygdala. In fact, Klüver-Bucy-like symptoms are mainly found in FTD, but 
amygdaloid atrophy was demonstrated, and considered rather typical of AD. The 
availability of techniques for manual tracing allowed us to investigate with good 
precision this aspect, and the results hinted at the disruption of a more complex circuit 
(Study II). Again, as in the case of the “pattern” approach, data derived from single 
structures attempt to associate function to activity in single structures, and equally 
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dysfunction to involvement of the “correspondent” structures. This way of interpreting 
functions and dysfunction is limited, and probably not true for complex cognitive 
functions. This problem has been partially overcome by the availability of new methods 
such as voxel based morphometry (VBM), allowing the investigators to compare at the 
same time all gray matter structures of groups of patients and controls, without pre-
selection of regions of interest that might preclude unexpected findings. The search for 
the involvement of a specific neural system, allowed by this technique, was motivated 
by the above imaging studies, and by the most recent data on neuropsychological and 
clinical performance of FTD patients (see section 2), that show apparently contradictory 
data such as only minor impairment in some frontal tests but severe behavioral 
inadequacy in their environment (study V). 
 
In addition to the studies aimed at defining which structures were involved in FTD, the 
characterization of the distribution of atrophy between the hemispheres and the impact 
of the APOE ε4 allele in FTD were investigated. With respect to distribution of atrophy, 
much has been written about mainly left or mainly right distribution in patients where 
language or behavior were, respectively, preferentially involved (Study III). Our data, 
mainly addressing a degree of asymmetry in the distribution of atrophy, also pointed to 
an influence of the APOE genotype. The ε4 allele of APOE is more frequent in FTD 
patients than in the normal population (Stevens et al., 1997), but it is not recognized as a 
risk factor for this condition. This observation, together with the knowledge that this 
kind of genotype seemed to impact on the distribution of atrophy, motivated us to 
investigate how the APOE ε4 allele modulates the morphologic phenotype of FTD 
(study IV).  
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4. MATERIALS AND METHODS 
 
 
4.1 Subjects 
 
The original dataset including the patients examined in this work was compounded of a 
total of 91 subjects (Frisoni et al, 1996): 14 patients with diagnosis of FTD, 46 with AD 
(33 with mild, 13 with moderate severity), and 31 normal controls. The number of 
patients (mainly AD, but also 4 controls and 1 FTD) was further reduced, for technical 
reasons (impossibility to transfer images from the optic disk to the CD). Moreover, 3 
FTD patients were not confirmed at follow-up evaluation (two were diagnosed as PPA, 
one displayed no deterioration over 3 years). As well, one control subject developed 
multi-system atrophy and was therefore excluded from subsequent analyses. In the 
course of study III, one FTD patient was observed to have an abnormal proportion of 
cerebral lobes and ventricles: this patient, included in the first studies, was excluded 
from the last ones, being considered as a morphological outlier, and study III initially 
considered 10 patients, but due to volumetric values of this study finally included only 
the other 9. The final numbers of our experimental groups were: 9 FTD (10 in studies I 
and II), 27 AD, 27 controls (26 in studies IV and V, because of the case who developed 
multiple-system atrophy). Availability of genotype information further reduced numbers 
in study IV. 
The demented were outpatients at the Alzheimer's Unit, Brescia, Italy. Routine 
dementia assessment and work-up were carried out in all patients. History was taken 
from a knowledgeable informant (usually the patient’s spouse), and was particularly 
focused on those symptoms that might help in the diagnostic differentiation of the 
dementia forms (implicit and explicit memory, language and executive functions, 
behavioral disturbances, disability in daily activities, hallucinations and other 
psychiatric symptoms, and falls). Laboratory studies included complete blood count, 
chemistry profile, chest x-ray, thyroid function, B12 and folic acid, electrocardiography, 
electroencephalography, and computed tomography scan. The neurological examination 
(including elicitation of primitive reflexes such as grasping, sucking, palmomental, and 
snout) was performed by a neurologist, and the physical examination by a geriatrician. 
A comprehensive neuropsychological battery taking about 90 minutes on average was 
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part of the routine assessment and included verbal and non-verbal memory, language 
and comprehension, limb praxis, visuo-spatial functions, frontal functions (Frisoni et al., 
1996). Individual tests that could not be carried out in those patients with more severe 
cognitive or linguistic impairment were not administered. However, all patients were 
able to complete at least 50% of the tests in the battery.  
In the original series (Frisoni et al., 1996), the diagnosis of FTD was made on clinical 
grounds based on pathologically verified clinical descriptions (Gustafson et al., 1987) 
and guidelines (the Lund and Manchester criteria) available at that time (Lund and 
Manchester groups, 1994; Miller et al, 1997). Behavioral aberrations were considered in 
relation to the diagnostic profile, but were not systematically recorded. After clinical 
evaluation, patients underwent single photon emission tomography (SPET) with HM-
PAO. All patients who satisfied the criteria for FTD before SPET imaging also showed 
anterior frontal or anterior temporal hypoperfusion (Frisoni et al., 1995). Thus, in the 
present study anterior hypoperfusion on SPET was confirmatory of a diagnosis 
independently made on clinical grounds. Moreover, the diagnosis of FTD was supported 
by the follow-up evaluations, carried out from a minimum of eight months to a 
maximum of three years. After excluding two patients with progressive aphasia in the 
absence of other cognitive and behavioral disturbances, one who displayed no 
deterioration in three years and the subjects from whom compatible data for volumetric 
analysis were not available, 10 FTD subjects remained. These were retrospectively 
assessed and judged to fulfill the recently published criteria for the diagnosis of 
frontotemporal lobar degeneration (Neary et al., 1998) of FTD type, representing a 
rather homogenous clinical phenotype. In the course of the present study, one more 
subject was excluded as a morphological outlier after the individual analysis of each 
pattern of brain volumes, which revealed an abnormal lobar proportion in this subject. 
Of the remaining patients, information about APOE was available from eight. 
AD patients fulfilled NINCDS-ADRDA criteria for probable AD (McKhann et al., 
1984). None of them had clinical features suggestive of dementia with Lewy Bodies 
(DLB), such as hallucinations, parkinsonism, sensitivity to neuroleptic medication, 
fluctuations, and falls. 
The vascular component for all the subjects was excluded on the basis of clinical 
assessment, computed tomography and MRI. 
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Although a formal behavioral assessment was not carried out in all patients at the time 
of MRI imaging, the Neuropsychiatric Inventory was administered to some patients at a 
later time (Rozzini et al., 1997), showing that FTD and AD patients had distinct 
behavioral profiles that were consistent with recent descriptions (Miller et al., 1997). 
The Italian version of the Mini-Mental State Examination (MMSE) was used to assess 
cognition (Magni et al., 1996). Of the original 46 AD patients, 27 had MRI images 
suitable for volumetric analyses of the present study, and 25 had information about 
APOE. 
For all patients, disease duration was computed from the estimated onset to the date of 
MRI imaging. The estimated onset was assessed from informants and defined as the 
time of the first appearance of memory, behavioral, language, or other symptoms that 
could be due to the degenerative brain disease. Overall dementia severity was assessed 
with the Clinical Dementia Rating scale (CDR) (Huges et al., 1982), which combines 
information on memory disturbances and daily function. Information on basic (bathing, 
dressing, grooming, walking, feeding, continence) and instrumental (using the 
telephone, shopping, cooking, doing housework, doing laundry, using public 
transportation, taking medications, and handling finances) activities of daily living was 
taken from a proxy informant. 
Controls were patients' relatives (mostly spouses) who themselves had no detectable 
cognitive deficit. They had a negative history of neurological disease, though some 
reported mild subjective memory problems which did not result in impairment of daily 
activities. All had MMSE administered, and were judged not to be demented by a 
neurologist and a psychologist involved in the evaluation of the patients. Of the original 
31 controls, 27 had MRI images suitable for volumetric analyses. During the course of 
this study, one developed multi-system atrophy and was excluded from subsequent 
analyses, that were thus carried out with 26 controls.  
Apolipoprotein E phenotyping was performed on patients and controls with isoelectric 
focusing on delipidated plasma samples (Kohlmeier et al., 1992). 
Written informed consent was obtained from both cases and controls or their primary 
caregivers, after discussion of risks and benefits of participation. No compensation was 
provided. The study was approved by the local ethics committee. 
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Although the patients groups were the same throughout the whole research project, 
some differences in patient selection occurred in each individual study, due to 
methodological needs.  
In Study III, the analysis of the individual patterns of atrophy revealed a very 
anomalous morphology of one FTD patient, who had abnormal lobar and ventricular 
proportions compared to controls. This subject was considered as a “morphological 
outlier”, and therefore excluded from all subsequent analyses. 
In Study IV, patient selection was obviously conditioned by the absence of missing 
values for the APOE genotype. Moreover, AD patients were selected based on age at 
onset, since there are data (Farrer et al., 1997) indicating that APOE genotype does not 
have any important impact when the disease occurs at a very early or very late age.  
 
 
4.2 Brain measurements  
 
MRI was performed in the Radiology Department, University of Verona with a 1.5 
Tesla unit (Siemens, Magnetom) and a standard head coil. A gradient-echo 3D-
technique was employed for image acquisition with: TR 10 msec; TE 4 msec; TI 300 
msec; flip angle 10°; field of view 250 mm; acquisition 2; matrix 160×256. Total 
acquisition time was 7:40 minutes. 
Brain measurements were carried out with traditional ROI-based methods, in a manual 
or semi-automated way, and with voxel by voxel comparisons (voxel based 
morphometry, VBM), a recent technique that requires sophisticated preprocessing by 
expert operators, but allows completely automatic comparisons between groups. 
 
 
4.2.1 ROI-based morphometry 
 
In order to carry out traditional volumetric analyses, images were transferred to a 
standard work consolle for manual tracing or to a Sun workstation (Sun Microsystem 
Inc., Mountain View, CA) for the semiautomated procedure, reassembled in order to 
reconstruct a 3D brain, aligned on the 3 dimensions in order to correct for tilting, and 
resliced into coronal slices 2 mm thick perpendicular to the AC-PC plane. 
41  
Alignment on the coronal plane was made on a slice where the sylvian aqueduct could 
be appreciated in its maximum length: a straight line was drawn from the lower wedge 
of the falx cerebri, to the lower visible point of the sylvian aqueduct. Alignment on the 
axial plane was done on a slice at the level of the lateral ventricles, where the anterior 
and posterior wedges of the falx cerebri were definite and symmetric: a straight line was 
drawn from the anterior to the posterior wedge of the falx cerebri. Alignment on the 
sagittal plane was conducted on the mid-sagittal slice, where the genu of the corpus 
callosum could be appreciated: a straight line was drawn from the point of convergence 
of the fornices to the lower margin of the superior culliculum. 
Traditional volumetric techniques then require an expert operator to select the regions of 
interest (ROIs) and trace their exact boundary (manual tracing) or a wide boundary 
containing the ROI (semiautomatic thresholding). The tracings are made on each slice 
where the target structure is visible, and their area is summed up and multiplied by slice 
thickness in order to compute the volume of the whole structure. 
As a measure of head size, we used the intracranial area (ICA), measured on a coronal 
section at the level of the anterior commissure and expressed in cm2. ICA was used to 
normalize brain volumes. 
Volumes of interest in this work were the frontal brain, frontal horns, temporal brain, 
temporal horns, and hippocampus and amygdalae. The right and left sides of these 
structures were measured and considered separately.  
 
 
4.2.1.1 Manual tracing 
 
Hippocampus. The hippocampus and amygdala were manually traced by expert 
operators following the visible boundaries on each slice where the structure appeared.  
In particular, the ROIs for the hippocampus were traced following a standardized and 
validated protocol. (Laakso et al., 1996) The volume of the hippocampus (considered as 
dentate gyrus, hippocampus proper, and the subicular complex) was measured starting 
from its appearance below the amygdala. The uncal portion of the rostral hippocampus 
that is located ventral to the caudal amygdala was included into the hippocampus. The 
tracing ended posteriorly in the section where the crura of the fornices depart from the 
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lateral wall of the lateral ventricles. Intraclass correlation coefficients for hippocampal 
measurements were 0.95 for intra-rater and 0.90 for inter-rater variability.  
 
 
Figure 1. 
Manual tracing 
of the hippocampus 
 
 
 
 
Amygdala. Volumes of the amygdalae were traced from where the amygdala forms the 
typical bulk in the medial temporal lobe. The tracing continued to the posterior by 
avoiding the hippocampus and the rhinal cortices until the disappearance of the 
amygdala above the hippocampus. The intraclass correlation coefficient for intra-rater 
reliability was 0.93. 
 
 
Figure 2. Location of the amygdala  
      above the hippocampus.  
 
 
 
 
 
 
 
Entorhinal cortex. The entorhinal volumes were traced according to the criteria by 
Insausti et al. (Insausti et al., 1998). The first slice measured was the one after the 
appearance of the limen insula when the temporal lobe can be first appreciated to be 
attached to the rest of the brain when proceeding from anterior, and the last slice was 
the one where the uncus and gyrus intralimbicus could no longer be appreciated. The 
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intraclass correlation coefficient for intrarater reliability for entorhinal volumes was 
0.90.  
 
 
Figure 3. Manual tracing of the entorhinal cortex (ENT), and its location relative to 
other brain structures visible in  
the same slice (a=amygdala,  
h=hippocampus, s=subyculum,  
rs=rhinal sulcus) 
 
 
 
 
 
 
 
 
4.2.1.2 Semiautomatic thresholding  
 
MRI images were analyzed with the software QUANTA (DeCarli etal., 1992). This 
combines manual tracing of a crudely defined region of interest (ROI) – completely 
comprising the structure to be measured – with an automatic thresholding procedure 
separating cerebrospinal fluid (CSF) from brain pixels. 
The segmentation of brain from non-brain tissue was carried out through several phases: 
histogram representation of pixels distribution (based on color gradients), gaussian 
modeling of the pixel distribution separately for CSF and brain pixels, and identification 
of the optimal cutoff to separate CSF from brain pixels on the basis of maximum 
likelihood functions (DeCarli et al., 1992). When the distribution of pixels was such that 
two separate gaussian functions could not be identified, the threshold was set manually 
in the graph representing the pixel distribution. This occurred only in the anteriormost 
ROIs of the frontal and temporal brain, comprising a relatively low number of pixels. 
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Figure 4:  
Gaussian modeling 
of the pixel distribution 
separately for CSF and  
brain pixels, and  
identification of the  
optimal cutoff to separate  
CSF from brain pixels on  
the basis of maximum 
likelihood functions. 
 
 
Tracing of the regions of interest. Tracing of ROIs was made on aligned coronal slices 
proceeding from anterior to posterior. The first ROIs, both for the frontal and temporal 
lobes, were traced on the slices where the brain matter could initially be appreciated, 
and the last ROIs on the slice where the sylvian acqueduct appeared. 
 
45  
Figure 5: Tracing of the frontal and  
temporal lobes and horns for the  
semiautomated thresholding procedure. 
 
 
 
 
 
 
 
4.2.2 Voxel by voxel brain measurements 
 
In the VBM method, the brains of groups of subjects are modified in a preprocessing 
phase, in order to fit a reference template, such that a stereotactic point refers to the 
same structure in each normalized brain. Then automatic statistical analyses are carried 
out, that compare the concentration of gray matter in each voxel. 
 
 
4.2.2.1 Preprocessing 
 
After removing the voxels below the cerebellum with MRIcro 
(www.psychology.nottingham.ac.uk/staff/cr1/mricro.html), MRI scans were analysed 
with SPM99 (www.fil.ion.ucl.ac.uk/spm) running under Matlab 6.0 (Mathworks, 
Sherborn, MA, USA) on a Sun Sparc Ultra 30 workstation (Sun Microsystem Inc., 
Mountain View, CA). The following pre-processing was carried out: creation of a gray 
matter template, normalization of the gray matter to the template, and smoothing. A 
complete description of the pre-processing procedures can be found elsewhere 
(Ashburner et al., 2000). Gray matter template. This is made through creation of a 
customized template of the whole brain, normalization of the original images to the 
template, extraction of the gray matter, and averaging. The customized template of the 
whole brain was obtained through normalization of the images of controls to the T1-
stereotactic template of SPM99 (Evans et al., 1994) using a 12-parameter affine 
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transformation followed by averaging of the normalized images. Then, the anterior 
commissure was identified and defined as the origin of the spatial coordinates 
(Ashburner et al., 1997).  
The normalization of the original images to the template was obtained through a 12-
parameter affine transformation. The gray matter of controls was then extracted 
through segmentation of images into gray matter, white matter, and CSF with a 
modified mixture model cluster algorithm and averaged thus obtaining a stereotactic 
customized gray matter template. 
Normalization. The gray matter of cases was extracted with the same procedure as 
described above for controls and together with the gray matter of controls, was 
normalized onto the gray matter template with affine and non-linear transformations, 
medium regularization, re-slicing 2 × 2 × 2 mm, and no masking (Baron et al., 2001). 
The resulting images were visually inspected one by one in order to exclude gross 
segmentation errors. 
Smoothing. The normalized gray matter images were smoothed with an isotropic 
Gaussian filter of 8 mm.  
 
 
4.3 Statistical analyses 
 
Statistical analyses were carried out with SPSS (SPSS Inc, Chicaco, IL) for all of the 
sociodemographic data and those from the manual tracings. For voxel based 
computations, statistical comparisons were carried out by the SPM99 program. 
 
 
4.3.1 ROI based volumetry 
 
Due to the low number of subjects of the FTD group, the significance of comparisons 
among groups was assessed by Mann-Whitney U-test. Significance between proportions 
was assessed by the Chi-square test. Pearson’s correlation coefficients were computed 
to address the effect of age on brain volumes and asymmetries. The critical level for 
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statistical significance was set at 0.05 for all tests.  
The effect of brain size was controlled by normalizing the volumes of the brain 
structures of interest by ICA with the formula: (volume/ICA×100). The combined effect 
of age and brain size was controlled for with a multivariate approach by transforming 
crude volumes into W-scores according to the formula:  
 
 
 (observed value) – (predicted age- and ICA-specific value in controls) 
W = ———————————————————————————————— 
standard deviation of residuals in controls 
 
where age- and ICA-specific values and residuals (the distance of each value from the 
regression line) in controls are computed by linear regression analysis (Jack et al., 1997) 
carried out on the 27 controls’ volumes of interest. W-scores are thus the distance in 
standard deviation units of an observed value from the expected age- and ICA-specific 
value.  
Brain asymmetry in the structures of interest was defined as the ratio of the right to the 
left crude value. For the effect of gender on brain asymmetry (Coffey et al., 1998), 
variables of asymmetry were expressed in age- and gender-specific W-scores (for the 
definition of asymmetry, correcting for ICA is superfluous). The loss of brain tissue was 
computed for both normalized volumes and W-scores and defined as the percent change 
with respect to mean control values (set at 100).  
In order to test the ability of atrophy variables to separate FTD from AD patients, 
multivariate discriminant analysis was used. This technique minimizes the overlap 
between the two groups by computing a multivariate function that allows a score 
(discriminant score) to be computed for each subject. The discriminant scores are such 
that they separate the two groups with the smallest possible overlapping, resulting in 
maximal overall sensitivity and specificity.  
Measures of atrophy expressed as W-scores contributing to the separation of the groups 
were assessed in discriminant models in two ways. The first approach (exploratory) 
consisted in building models with a priori selection of variables, chosen on the basis of 
clinical plausibility. The second approach (algorithmic) consisted of testing the 
independent contribution of each variable in the separation of FTD from AD through a 
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stepwise selection algorithm. This enters into the model the variables that contribute 
(based on the smallest Wilks’ λ of the discriminant function, and on F-to-enter for 
Wilks’ λ greater than 3.0), and excludes those variables that do not contribute to 
separating the groups (based on F-to-remove values for Wilks’ λ lower than 2.0). 
Likelihood ratios (LR) (Simel et al., 1993) computed as sensitivity/(1-specificity) and 
95% confidence intervals (CI) (Simel et al, 1991) are provided for each discriminant 
model. CI were computed with the logarithmic method (Gardner et al., 1989). 
For the more specific analysis of symmetry of atrophy in FTD, symmetry of the 
frontotemporal atrophy was operationalized as the difference between right and left W-
scores lower than 1 both in the frontal regions (mean between brain and horns) and in 
the temporal regions (brain and horns). 
 
  Δ FB + Δ FH                   Δ TB + Δ TH 
—————— <1 AND ——————— <1 
2      2 
 
where Δ indicates the difference between right and left.  
 
If the patient had a difference higher than 1 (mean between brain and horn) in the 
frontal or in the temporal lobe, the patient was classified as being asymmetric. 
 
 
4.3.2 VBM 
 
In the comparisons carried out with the SPM99 program, the “Compare populations – 
AnCova” procedure was used to compare the gray matter concentration between cases 
and controls, and statistical significance was set at p<0.05 corrected for multiple 
comparisons. Age was used as a covariate. 
In the VBM comparisons, patients carrying the ε4 allele versus the non carriers, the 
“Single Subjects – Conditions and Covariates” procedure was used to compare the 
gray matter concentration between carriers and non carriers. The regions specifically 
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atrophic in patients carrying and not carrying the ε4 allele were detected by contrasting 
all patients to controls and inclusively masking atrophy of the carriers relative to that 
of the non carriers and vice versa. Statistical significance was set at p<0.05 corrected 
for multiple comparisons. Age and sex were used as nuisance variables for all subjects. 
In FTD, the MMSE score was also entered as a nuisance variable in order to correct for 
the different cognitive level that was found between carriers of the ε4 allele and the 
non-carriers.  
 
 
5. RESULTS 
 
5.1 Clinical and sociodemographic features of patients and controls. 
 
FTD were relatively younger and more often men than AD patients and controls (Table 
3). Overall, dementia severity was similar between FTD and AD patients. Although 
FTD patients scored 4 points lower than AD patients on the MMSE, global severity of 
dementia and functional impairment were not different. Language disturbances were 
more frequent and severe in FTD (50 vs. 4%), and the difference in the MMSE was 
interpreted as being a consequence of this difference (Frisoni et al., 1999). The 
frequency of the ε4 allele in FTD was intermediate between that of AD patients and 
controls. Brain size was smaller in AD patients.  
The same pattern of differences was found in all of the five studies, although the 
number of subjects differed slightly due to methodological reasons (see methods).  
Cognitive performance as measured at neuropsychological tests was not a final 
objective of these studies, rather it had been considered during the diagnostic process. 
Anyway, FTD patients showed, besides the fall in performance at classical frontal tests 
(WCST, verbal fluency, etc.), a pattern of selectively preserved memory compared to 
AD, and had better performance at logical and verbal memory. Performance at Rey’s 
figure trials showed lower performance at the copying task, but better performance in 
the recall task (Frisoni et al, 1996). Topographic disorientation was entirely absent in 
the FTD group, while the linguistic function displayed impairment in FTD, and was 
almost intact in AD. Recording of aberrant behavior or altered dietary habits had double 
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frequency compared to AD (Frisoni et al, 1999).  
 
 
Table 3. Clinical and demographic features of patients and controls as in study I. 
 
 FTD  AD  Controls  
 n=10  n=27  n=27  
Age, years 63 (5) *  73 (9) †  70 (8) †  
Sex, men 7 (70%) *  5 (19%) †  10 (37%) †  
Education, years 7 (4)  7 (4)  8 (3)  
Disease duration, months 30 (14)  42 (26)  -  
Mini-Mental State 
Examination 
16 (9) *  20 (4) *  29 (1) †  
Clinical dementia rating       
0 0 0 27 (100%) 
0.5 4 (40%) 8 (30%) 0 
1 2 (20%) 11 (40%) 0 
2-3 4 (40%) 
 
    * 
8 (30%) 
 
  * 
0 
 
 † 
Instrumental Activities of 
Daily Living, n. of 
functions lost 
3.0 (2.4)  3.7 (2.4)  -  
ApoE ε4, n/total alleles § 3/18 (17%)   18/50 (36%) *  5/50 (10%) †  
Intracranial area, cm² 174 (11) †  162 (11) *  169 (13) †  
 
Values denote mean (standard deviation) or number (percentage). 
* † ¶ groups with different marks are significantly different on Mann-Whitney or χ2 
tests. No marks denotes no difference between groups. 
§ ApoE phenotyping was performed in 9 subjects with FTD, 25 with AD, and 25 
controls. 
 
 
5.2 The pattern of atrophy as a biological marker (Study I) 
 
The research question in this study consisted in defining the pattern of volumes of a set 
of key structures rather than of a single structure, that could have a satisfying 
discriminative power in the separation of FTD and AD. 
When the effect of age (younger in FTD) was taken into account with the computation 
of W-scores, atrophy in the left frontal regions was found to be greater in FTD than in 
AD patients. The difference was more marked in the left frontal horn (p=0.008 on 
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Mann-Whitney test) than brain matter (p=0.01). A non-significant tendency for more 
atrophic temporal brain matter and larger temporal horns was found in FTD compared 
to AD, but only approached statistical significance in the right temporal brain (W-scores 
of –2.1 and –1.3, p=0.07) (Table  4). 
The low power of the volumes of single brain structures in the discrimination between 
AD and FTD lead us to consider a more complex pattern including a group of relevant 
structures rather than one single structure. 
 
 
Figure 6. Pattern of atrophy in AD and FTD 
 
 
Within each diagnostic group, atrophy was distributed differently across regions (Figure 
6). In FTD patients, the regions showing the overall greatest atrophy were the temporal 
regions (average W-scores across right and left brain and horns: -2.9, SD 2.4), mildly 
less atrophic were the frontal regions (-2.4, SD 2.1), while the hippocampi showed the 
least atrophy (average W-scores across right and left hippocampi: -1.3, SD 1.5). The 
atrophy profile of AD patients was different in that the most atrophic regions were the 
temporal (-1.9, SD 1.8) and the hippocampi (-1.8, SD 0.9), while relatively less atrophic 
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were the frontal regions (-0.9, SD 1.5). In both the frontal and temporal regions, the 
most accurate markers of atrophy were the ventricle horns.  
 
 
5.2.1 Correlation of atrophic regions with cognitive function 
 
The regions more strongly associated with disease severity (as indicated by the MMSE) 
in FTD were the left temporal and frontal brain (r=0.71, p=0.02 , and r=0.60, p=0.06) 
whereas in AD it was the right temporal horn (r=0.38, p=0.05). 
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Table 4. Regional brain measures of frontotemporal dementia (FTD) and Alzheimer's disease (AD) patients and controls. 
  Crude values Normalized for cranial size Normalized for cranial size and age 
        % diff. 
from 
controls 
  % diff. 
from 
controls 
  FTD AD controls FTD AD controls FTD AD FTD AD FTD AD 
Frontal lobe                  
   Brain R 180 (31) 173 (22) 196 (19)  1032 (157) 
*
1066 (131) * 1160 (108)  11 8  -1.7 (2.0) * -0.9 (1.2) *  12 7 
 L 170 (25) 171 (21) 193 (19)  977 (140) * 1058 (128) * 1143 (112)  14 7  -2.6 (1.9) † -0.8 (1.2) *  17 6 
   Horn R 14.7 (6.4) 13.1 (6.2) 9.1 (5.6)  85 (38) * 80 (39) * 53 (31)  61 52  -2.1 (2.1) * -0.8 (1.6) *  121 46 
 L 17.6 (6.8) 13.3 (6.3) 8.9 (4.4)  102 (41) * 82 (39) * 52 (24)  96 57  -3.1 (2.3) † -1.1 (1.8) *  182 53 
Temporal lobe                  
   Brain R 37.3(11.6) 37.5 (6.6) 53.1 (10.4)  213 (62) * 232 (43) * 313 (57)  32 26  -2.1 (1.2) * -1.3 (0.7) *  35 24 
 L 35.6 (10.1) 35.5 (6.5) 46.3 (6.5)  204 (56) * 220 (45) * 273 (29)  25 20  -2.5 (1.9) * -1.6 (1.4) *  26 19 
   Horn R 1.4 (0.9) 1.6 (0.9) 0.7 (0.4)  8 (6) * 10 (5) * 4 (2)  105 141  -2.6 (3.0) * -2.2 (2.4) *  161 109 
 L 1.6 (0.9) 1.3 (0.9) 0.5 (0.4)  9 (5) * 8 (5) * 3 (2)  211 180  -4.3 (3.3) * -2.6 (2.8) *  316 135 
Hippocampus                  
 R 1.6 (0.5) 1.3 (0.4) 1.9 (0.4)  9 (3) * 8 (2)* 12 (2)  23 33  -1.5 (1.4) * -1.7 (0.9) *  25 33 
 L 1.5 (0.5) 1.2 (0.3) 1.8 (0.3)  9 (3) 7 (2) † 11 (2)  17 30  -1.2 (1.7) † -1.9 (0.9) *  18 32 
 
Values denote mean (SD) values of crude volumes (in cm3), of volumes normalized for cranial size (computed with the formula: volume/ICA*100) 
(ICA=intracranial area), and of atrophy, corrected for cranial size and age (W-scores). W-scores are age- and head size-specific normalized distances 
(in standard deviation units) of patients' measures of atrophy from the specific expected value, computed from the distribution of normal controls. 
Horns volumes are polarized, so that greater atrophy is denoted by greater negative values in all cases. 
* significantly different from controls and † from controls as well as from the other patient group according to Mann-Whitney test. 
No mark denotes no difference between groups. 
Percent change denotes the difference with controls in normalized values and in age- and head size-specific W-scores. Greater positive values denote greater atrophy in 
all cases. 
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5.2.2 Interhemispheric distribution of atrophy in AD and FTD 
 
Figure 6 also shows that atrophy was more asymmetrical in FTD than AD patients 
throughout all frontal and temporal regions, though this was most evident in the 
temporal horns. Asymmetry values, indicated by the right/left ratios, of the temporal 
horns were 0.88 (SD 0.39) in FTD, 1.29 (0.47) in AD, and 1.60 (1.25) in controls, 
indicating that the left temporal horn was relatively more enlarged in FTD patients than 
in controls (p=0.008), while the difference was not significant between AD patients and 
controls (p=0.39). This asymmetry pattern was even clearer when right/left ratios were 
expressed in W-scores, allowing us to control for the normal effect of age and gender on 
asymmetry. W-scores were -1.27 (SD 0.61) in FTD, and 0.05 (0.55) in AD patients. The 
difference was significant between FTD and controls (p=0.0002), non-significant 
between AD and controls (p=0.47), and significant between FTD and AD patients 
(p<0.00005). The W-scores of asymmetry were computed for the other brain regions, 
indicating overall greater asymmetry with prevalent left atrophy of FTD (absolute 
values of W-scores ranging between 0.64 and 1.14) vs. AD patients (0.12 to 0.27). 
 
 
5.2.3 The pattern of atrophy as a discriminating tool in the differential diagnosis from 
AD 
 
The discriminant exploratory models (Table  5) were built based on the W-scores of 
single regions (each including brain and horns) and on W-scores of asymmetry in two 
or more regions. The final exploratory model included the two previous models (the 
fifth and sixth in Table 5) that best discriminated patients groups, and achieved a 
sensitivity of 90% and specificity of 93% in the discrimination of FTD from AD. The 
algorithmic approach selected two variables that separated the two groups with lower 
sensitivity (80%) but higher specificity (96%). 
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Table 5. Separation of FTD from AD patients by regional atrophy measures. 
 
Model   Correct classification  
  AD (n=27) FTD 
(n=10)
LR (95% CI) 
Exploratory  1) RFB, RFH 20 (74%) 5 (50%) 1.9 (0.8 to 4.7) 
 2) LFB, LFH 22 (82%) 7 (70%) 3.8 (1.5 to 9.2) 
 3) RTB, RTH 18 (67%) 5 (50%) 1.5 (0.7 to 3.4) 
 4) LTB, LTH 18 (67%) 6 (60%) 1.8 (0.9 to 3.7) 
 5) AsyFB, AsyTB 23 (85%) 8 (80%) 5.4 (2.1 to 14.0) 
 6) AsyFH, AsyTH 24 (89%) 8 (80%) 7.2 (2.4 to 21.8) 
 7) AsyFH, AsyTH, 
    AsyFB, AsyTB 
25 (93%) 9 (90%) 12.1 (3.2 to 46.8) 
Algorithmic AsyTH, RTB 26 (96%) 8 (80%) 21.6 (3.1 to 151.2) 
 
RFB = right frontal brain, LFB = left frontal brain, RFH = right frontal horn, LFH = left 
frontal horn, RTB = right temporal brain, LTB = left temporal brain, RTH = right 
temporal horn, LTH = left temporal horn, AsyFB = asymmetry of frontal brain, AsyFH 
= asymmetry of frontal horns, AsyTB = asymmetry of temporal brain, AsyTH = 
asymmetry of temporal horns,. 
LR: likelihood ratio. CI: confidence interval. 
Classification figures were computed with a discriminant function algorithm on the 
basis of age and head-size specific scores (W-scores, see Table 4). 
 
 
5.3 Amygdaloid atrophy in FTD and AD (Study II) 
 
Objective of this study consisted in investigating amygdaloid volumes with comparison 
to both AD and control groups, given the counterintuitive observation that Klüver-Bucy 
symptoms, known to derive from amygdaloid damage, are more frequently registered in 
FTD patients rather than in AD, where amygdaloid atrophy has been repeatedly 
ascertained.  
The analysis of the amygdalae in AD and FTD showed that their normalized volumes 
were different from control values in both demented groups: FTD vs. controls 
(p<0.005), AD vs. controls (p<0.0005), but not between the two patient groups 
(p>0.15). However, there was a trend for increasing atrophy from controls, through 
FTD, to AD (p for trend <0.00005) (Table 6).  
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The comparisons of the FTD amygdaloid volumes were also carried out without a 
subject with motor neuron disease, where amygdaloid metabolism was already 
demonstrated to be lower than in controls (Garraux et al., 1999). Normalized volumes 
of this subject were 0.726 and 0.632 for right and left amygdala, and the results of 
comparisons among groups did not change.  
 
 
5.3.1 A disconnection hypothesis for behavioral symptoms in FTD 
 
As FTD patients are characterized by behavioral disturbances, some of which are 
typically due to amygdaloid damage, actually more severe in AD, the hypothesis arose 
that behavioral disturbances require not only amygdaloid damage, but also a disruption 
of their connection to the frontal lobes, which are functionally associated to the limbic 
areas, particularly to the amygdala. This disconnection hypothesis was provisionally 
tested by computing the ratio between the frontal lobes and amygdaloid volumes, and 
correcting it by age. The W-scores of this ratio (W=0.6 + 1.4 versus 2.1 + 2.0; p=0.04) 
indicated larger frontal relative to amygdaloid volume in AD patients, which is 
compatible with the hypothesis of a greater preservation of the fronto-limbic circuitry 
helping control of this kind of behavior in these patients. 
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Table 6. Crude and corrected amygdaloid and frontal volumes 
 
Amygdalae 
  Crude values, cm3 Normalized values Loss, % 
  right left right left right left 
Controls  1.16 (0.18) 1.11 (0.17)  0.91 (0.13) 0.87 (0.11) 0.0 0.0 
FTD  0.96 (0.26) 0.88 (0.19)  * 0.74 (0.21) * 0.69 (0.16) 18.6 21.6 
AD  0.77 (0.17) 0.78 (0.20)  * 0.64 (0.15) * 0.64 (0.18) 30.2 26.3 
Frontal lobes 
  Crude values, cm3  Normalized values (W-scores) Loss, % 
  right left right left right left 
Controls  196 (19) 193 (19) Ref (0.0) Ref (0.0) 0 0 
FTD  180 (31) 170 (25) *-1.7 (2.0) †-2.6 (1.9) 12 17 
AD  172 (23) 170 (21) *-0.9 (1.2) *-0.8 (1.2) 7 6 
 
*Difference from the unmarked group on Mann-Whitney U test and † between 
groups.  
Normalized values are volumes corrected for cranial size. Percent loss is computed with 
respect to the mean normalized volumes of the control subjects. W-scores are obtained by 
dividing the difference between the observed volume and the expected volumes for a 
subject of the same age and cranial size by the standard deviation of residuals in controls. 
Expected values and residuals are computed in controls with a linear regression analysis 
where age and cranial size are independent variables. By definition, the W-scores of 
controls are equal to 0 and negative values indicate shrinkage. 
 
 
 
 
 
 
5.4 Symmetric versus asymmetric phenotype of FTD (Study III) 
 
Aim of this study was to try identify whether a different distribution of atrophy 
(symmetrical versus asymmetrical), that is variably reported in different studies was 
associated to clinical or other differences in disease presentation. 
Quantification of the symmetry of atrophy distribution distinguished 3 patients with 
symmetric atrophy and 6 with clearly asymmetric atrophy (Figure 7). 
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Figure 7. Examples of symmetric and asymmetric patients with frontotemporal 
dementia. 
 
 
 
Upper part: MR scan. Lower part: quantification of atrophy with W-scores (see 
methods).  
FB = frontal brain, FH = frontal horn, TB = temporal brain, TH = temporal horn. 
▲= right ■ = left. Negative W-scores indicate shrinkage, positive values indicate 
enlargement. Note different scales of atrophy.  
 
 
 
“Symmetric” patients had greater atrophy in the frontal and temporal regions (Table 7). 
Moreover, medial temporal atrophy was absent, or rather minor in the asymmetric, and 
markedly greater in the symmetric patients. The difference between the two groups was 
close to statistical significance for the hippocampi, and significant for the entorhinal 
cortex. Global values of frontotemporal, medial temporal and overall atrophy indicate 
significantly greater atrophy in symmetric patients.  
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Table 7. Atrophy of frontal, temporal and medial temporal regions in the symmetric and 
asymmetric groups. 
 
 
Values denote mean (SD) values of atrophy expressed as W-scores. Overall values of 
atrophy are the W-score of the sum of crude right and left frontal and temporal brain 
and horns (overall frontotemporal), right and left hippocampus and entorhinal cortex 
(overall medial temporal, and of all brain regions considered in the study (overall 
atrophy). * Polarized so that negative values indicate atrophy. p = significance in Mann-
Whitney test. 
Region  Symmetric 
n = 3 
Asymmetric 
n = 6 
p 
Frontal region    
    Brain R -3.78 (0.47) -0.91 (1.70) 0.04 
 L -4.09 (0.32) -2.20 (2.01) n.s. 
    Horn* R -4.49 (1.33) -1.41 (1.09) 0.04 
 L -5.03 (0.91) -2.94 (1.52) 0.07 
Temporal region    
    Brain R -3.82 (0.17) -1.38 (0.55) 0.02 
 L -4.07 (0.46) -1.75 (2.11) n.s. 
    Horn* R -5.43 (2.49) -1.86 (2.29) n.s. 
 L -5.22 (2.14) -4.71 (3.53) n.s. 
Overall fronto-temporal atrophy  -6.61 (1.05) -2.72 (1.69) 0.02 
Medial temporal region    
    Hippocampus R -2.87 (1.32) -0.97 (1.18) 0.07 
 L -2.59 (1.83) -0.82 (1.23) 0.07 
    Entorhinal cortex R -3.18 (0.26) -0.76 (1.16) 0.02 
 L -2.38 (0.81) -0.92 (1.03) 0.04 
Overall medial temporal atrophy  -3.46 (1.13) -1.22 (1.16) 0.04 
Overall atrophy  -3.66 (1.11) -1.31 (1.19) 0.04 
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5.4.1 Clinical correlates of the symmetric phenotype and putative link with APOE 
 
The patients with a symmetric phenotype, in spite of similar disease duration and 
clinical severity, had a younger age at onset of disease (53 ± 2.0 vs. 62 ± 2.5, exact p = 
0.02), and a higher prevalence of the ε4 allele of the apolipoprotein E (50% vs. 0%, p = 
0.02).  
 
 
5.5 APOE as a modulator of the clinical phenotype of degenerative diseases (Study 
IV) 
 
In this study, the role of APOE in the disease expression was investigated, after the 
observation (study III) that FTD patients with symmetrical atrophy have higher 
representation of the ε4 allele. 
 
 
5.5.1. Sociodemographic features 
 
In this study, AD patients were selected based on age at onset of dementia, in order to 
exclude very early and very late age at onset, where the effect of APOE is questionable 
(Farrer et al., 1997). Nonetheless, age and age at onset closely reflected those of 
unselected patients, since both lower and higher values were excluded, and thus differed 
significantly from the younger group of FTD, resembling the same pattern of 
sociodemographic features as in the other studies. 
Comparisons of patients carrying and not carrying the ε4 allele within each patient 
group indicated that the ε4+ AD subjects were 100% women, differing significantly 
(p=0.02) from the ε4- subjects. 
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5.5.2 Volumetry of ε4 carriers and non carriers 
 
Voxel by voxel analyses showed significantly greater atrophy of the amygdalae and 
head of hippocampi in the AD patients carrying the allele compared to the non carriers 
(Table 8, Figure 8a). FTD patients carrying the ε4 allele were characterized by greater 
right lobar atrophy, evident in the frontotemporal regions at uncorrected p (Figure 8b), 
and with a single cluster in the right ventral striatum at p corrected for multiple 
comparisons (Table 8). 
The opposite comparisons (non carriers versus carriers) did not reveal any significant 
changes in voxels densities in any of the patient groups, indicating lower severity of 
atrophy of the ε4- subjects. 
 
 
Table 8. Atrophic regions in AD and FTD patients carrying the ε4 allele vs the non 
carriers, at p<0.05 corrected 
 
Cluster 
size 
 Region  Stereotactic 
coordinates 
Z 
   x y z  
  AD ε4+ vs ε4- 
121  L amygdala -22 -6 -14 6.24
  L amygdala -24 2 -22 5.66
60  R amygdala 22 2 -22 5.19
1  R hippocampal tail 24 -36 2 4.89
  FTD ε4+ vs ε4- 
10  R ventral striatum 10 22 -20 5.42
 
Reading example: the first line denotes the presence of a 3D cluster made of 121 
contiguous voxels of significantly decreased (p<0.05 corrected for multiple 
comparisons) gray matter density. The most significant voxel of the cluster has 
stereotactic coordinates of –22, -6, -14, and is located in the left amygdala. Within the 
same cluster there is a second peak of significance more than 8 mm distant from the 
former and located at -24, 2, -22. 
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Figure 8. A) Atrophy in AD patients carrying the ε4 allele vs the non carriers at p<0.05 
corrected. B) Atrophy in FTD patients carrying the ε4 allele vs the non carriers (for 
illustrative purposes, the FTD figure shows atrophy at p<0.001 uncorrected) 
 
A)         B)  
 
 
5.6 Frontotemporal dementia as a neural-system disease (Study V) 
 
FTD is characterized by frontal atrophy, but neuropsychological tests for frontal 
function often fail to detect anomalies during the early stages of disease. As has been 
demonstrated for neurological frontal patients, disruption of a circuit including the 
frontal structures might be primarily involved as the origin of the disease, rather than 
damage to the frontal lobes per se. This analysis of global brain atrophy in FTD, 
allowed by the VBM techniques that became available during the course of these 
studies, was aimed to test the hypothesis that a circuit involved in the control of 
behavior could be disrupted. The anterior limbic system, which is known for 
controlling adaptive behavior, was the main candidate, and some of its structures were 
already demonstrated to be atrophic in previous studies. 
As shown in table 9, five regions of the rostral limbic system were indeed atrophic in 
FTD at p<0.05 corrected for multiple comparisons. Particularly large areas of atrophy 
were found in the anterior cingulate and ventromedial frontal cortex, but the right 
ventral striatum, posterior amygdalae, and anterior insulae were also involved. 
FTD .001 
uncorrected 
AD .05 
corrected
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The periaqueductal gray, the only region constituting the rostral limbic system that was 
not atrophic at p<0.05 corrected, displayed atrophy at p<0.001 uncorrected (Figure 9).  
Isolated spots of atrophy were noted in the left frontal gyri including Broca’s area and 
in the left inferior temporal gyrus (Table  9). 
 
Table 9. Atrophic regions in frontotemporal dementia. 
Cluster 
size 
 Region  BA Stereotactic 
coordinates 
 Z 
         
147 * L ventromedial PFC 10 -2 44 -10  5.52 
 * R/L anterior cingulate 32 0 26 -10  5.07 
32 * L anterior insula - -38 30 2  5.44 
 * L anterior insula - -32 22 10  5.43 
19 * R ventromedial PFC 25 4 6 -6  5.36 
8  L Broca’s area 44 -52 8 18  5.27 
20 * R posterior amygdala  - 18 -10 -14  5.16 
14  L inferior temporal gyrus 20 -62 -28 -24  5.14 
8 * R ventromedial PFC 11 8 18 -18  5.08 
2  L dorsolateral PFC 9 -4 50 24  5.06 
23 * L posterior amygdala  - -18 -10 -14  5.02 
6 * R anterior insula - 38 22 8  4.95 
3 * R caudate head - 14 20 -2  4.92 
1 * L anterior cingulate 32 -4 32 18  4.84 
5 * L anterior cingulate 32 -8 14 38  4.83 
2  R uncus 28 18 -6 -22  4.80 
4 * R anterior cingulate 32 10 22 36  4.78 
2 * R anterior cingulate 32 8 34 26  4.77 
1  L dorsolateral PFC 9 -4 46 24  4.77 
 
R = right, L = left, PFC = prefrontal cortex, BA = Brodmann area. Cluster size is in number of 
voxels. 
Reading example: the first line denotes the presence of a 3D cluster made of 147 contiguous 
voxels of significantly decreased (p<0.05 corrected for multiple comparisons) gray matter 
density. The most significant voxel of the cluster has stereotactic coordinates of –2, 44, -10, and 
is located in the left ventromedial frontal cortex (Brodmann area 10). Within the same cluster 
there is a second peak of significance more than 8 mm distant from the former and located at 0, 
26, -10.  
* Region belonging to the rostral limbic system.  
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Figure 9. Atrophic regions in frontotemporal dementia and anatomic structures 
belonging to the rostral limbic system. 
a) Structures atrophic in frontotemporal dementia compared to controls. For illustrative 
purposes, atrophy at p<0.001 uncorrected is shown.  
b) The rostral limbic system includes 1) the anterior cingulate cortex 2), the anterior 
insula, 3) the ventral striatum, 4) the ventromedial prefrontal cortex (including the gyrus 
rectus), 5) the amygdalae, and 6) the periaqueductal gray. 
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6. DISCUSSION 
 
 
6.1 Compound volumetric measures as discriminative tools in the differential 
diagnosis 
 
The single region markers are unsatisfactory if one whishes to differentiate patients with 
FTD from AD patients (Frisoni et al., 1999). Moreover, this approach has the 
disadvantage of being strongly dependent on the stage of the disease, given the 
progressive nature of atrophy in all regions, at least in AD (Fox et al., 1999; Fox et al., 
2000; Jack et al., 2000. This study, analyzing a wider set of structures, indicated that 
FTD is characterized by a particular pattern of atrophy where the hippocampus exhibits 
mild atrophy, while the frontal and the temporal regions suffer strikingly more severe 
atrophy. The pattern is different from that of AD patients, who show moderate 
hippocampal atrophy, temporal atrophy of similar degree, and milder frontal atrophy. 
Moreover, FTD patients exhibit greater asymmetry, with the left regions being more 
atrophic than the right. It should be stressed that this approach might identify a constant 
pattern of atrophy, that does not vary through different stages of disease severity.  
When used as a discriminative tool, the atrophy profile approach proved to be 
satisfactory, with specificity values of 93% and sensitivity of 90%, where single, albeit 
typical, structure-based approach did not discriminate at all among groups in the same 
patients (Frisoni et al., 1999). 
 
 
6.1.1 Symmetry as additional information in the pattern approach 
 
FTD is known to be an asymmetrical disease. For example, the early impairment of 
language indicates that the left hemisphere is more involved than the right (Grossman et 
al, 1996), while behavioral symptoms seem to be associated with a greater involvement 
of the right hemisphere (Mychack et al., 2001). In accordance with this hypothesis, 
asymmetrical hypoperfusion has repeatedly been demonstrated with SPET studies of 
FTD (Frisoni et al., 1995; Miller and Gearhart, 1999). However, structural imaging 
studies have paid little attention to atrophy asymmetry. A laterality index has been 
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computed (Kitagaki et al., 1998) on the basis of hemispheric volumes, and from the data 
reported in the paper the sensitivity and specificity can be computed to be around 40 
and 95%. The authors did not compute a regional laterality index for the frontal and 
temporal regions. Since moderate to severe cortical atrophy in the anterior superior 
temporal region alone was able to correctly classify 13/18 FTD and 16/18 AD patients 
(sensitivity and specificity of 72 and 89%), it can be hypothesized that a regional 
laterality index in these areas might have yielded even higher figures. It is significant 
that in our sample the asymmetry of the frontal and temporal horns alone was able to 
discriminate FTD from AD patients with 80% sensitivity and 89% specificity. 
Nonetheless, a laterality index is not sufficient itself as a marker for the differentiation 
of FTD and AD, first, because the small sample size of our patient group does not allow 
us to make wider generalization, secondly, because evidence exists that some FTD 
patients might have symmetric atrophy (Miller and Gearhart, 1999).  
 
 
6.2 The failure of the single structure approach in understanding the nature of the 
disease 
 
As no single structure marker has proved sufficient in discriminating FTD from AD, the 
analogous attempt to explain the FTD syndrome based on the most typically affected 
structure (i.e. the frontal lobe) has been equally ineffective. The first hint of this 
problem came from Study II, where evidence of similar extents of amygdaloid atrophy 
were observed, but very different “amygdaloid-related” symptoms were exhibited in 
AD and FTD. 
Previous studies on amygdaloid function or volume have not detected any amygdaloid 
involvement in FTD (Garraux et al., 1999; Rosen et al., 2002). This claim, which in fact 
does not seem compatible with the typical FTD symptoms (Neary et al., 1998), is not 
confirmed by our work, since we detected a tissue loss of about 20% in the amygdalae 
of the FTD group. Moreover, the amygdaloid atrophy tended to be greater in AD 
patients, up to 30%.  
After the experiments of Klüver and Bucy on monkeys, symptoms like hyperorality, 
hypersexuality, absence of fear have also been related to amygdaloid involvement in 
man (Marlow et al., 1975; Lily et al., 1983; Gerstenbrand et al., 1983). The fact that 
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amygdaloid atrophy appeared to be less extensive in FTD than in AD in our study is not 
consistent with the clinical observation that symptoms considered to be largely due to 
amygdaloid damage are more frequent in FTD than in AD (Förstl et al., 1993; 
McKhann et al., 1984; Neary et al., 1998). One possible explanation might be that these 
symptoms are not due to amygdaloid damage per se, but to disruption of a neural 
system including this structure. This might include the frontal lobes, which are 
particularly damaged in FTD (Fukuy and Kertesz, 2000) and which have close 
connections with the amygdalae (Szesko et al., 1999). This view is supported by the 
greater frontal/amygdaloid ratio in AD as compared to FTD patients, indicating a 
disproportionate frontal preservation in AD compared to FTD. This explanation for 
Klüver-Bucy-like symptoms is based on results obtained through mathematical 
modeling of the frontal/amygdaloid ratios in order to account for the effect of younger 
age in FTD patients, and will need to be replicated in age-matched groups. 
However, the hypothesis is consistent with findings of other authors, who, contrary to 
expectations, found Klüver-Bucy-like symptoms in patients without amygdaloid 
involvement, and attributed them to disruption of fronto-limbic connections (Carrol et 
al., 2001; Takahashi and Kawamura, 2001). 
 
 
6.3 Different phenotypes of FTD  
 
Frontotemporal lobar degeneration syndromes are characterized by different symptoms 
accompanied by differential involvement of brain regions (see section 2.2 about clinical 
criteria). When a frontal or a temporal variant of FTD (fvFTD or tvFTD respectively) 
are mentioned in the current literature, they actually refer to FTD or semantic dementia, 
which are already recognized as discrete clinical entities in the most widely used 
clinical criteria (Neary et al., 1998). When individual phenotypes of FTD are 
considered, based on the specific pattern of atrophy of each patient, a greater right or 
left involvement has been described (Mychack et al., 2001). 
In our FTD patient group, we did not find any evidence of subjects with right versus left 
hemispheric involvement. When subjects had significant right atrophy, they also 
exhibited left atrophy to the same degree, almost as if left hemispheric atrophy was a 
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constant feature of the disease. More exactly, a minority of our patients (30%) presented 
with symmetric frontotemporal and medial temporal atrophy, of a more severe degree 
compared to those patients with an asymmetric involvement.  
Some relevant observations can be made. First of all, the patients with symmetric 
atrophy had an earlier onset of disease. Second, they presented with more severe global 
and medial temporal atrophy despite equal global clinical severity duration. Third, in 
the patients with asymmetric disease, only the left frontal and temporal regions were 
affected, while right frontotemporal and bilateral medial temporal regions were only 
mildly atrophic. Finally, the patients with symmetric presentation also had greater 
frequency of the ApoE ε4 alleles, while no patients with asymmetric atrophy carried this 
allele. 
The asymmetric involvement of the brain in FTD is viewed as the cause of the wide 
variety of symptoms of this type of dementia (mainly linguistic or behavioral, 
considered to represent left and/or right involvement, respectively) (Mychack et al., 
2001). Symmetric involvement would imply that both linguistic and behavioral 
symptoms are both present and severe, but lack of detailed data of our patients from 
earlier does not allow us to test this hypothesis.  
A more symmetric distribution of atrophy might be due to a very advanced stage of 
disease, and represent a floor effect. Our symmetric patients had a mean disease 
duration 5 months longer than the asymmetric subjects. As the initial pattern of atrophy 
in the degenerative dementias has been shown to remain unchanged as the disease 
progresses for at least 2-3 years (Smith et al., 1992), it does not seem likely that the 
minor difference of disease duration is responsible for the different distribution of 
atrophy in our groups. 
 
 
6.4 Influence of the APOE genotype on the phenotype of FTD 
 
In Study III, “symmetric” FTD patients had a higher percentage of the APOE ε4 allele, 
that was not detected at all in the genotype of “asymmetric” subjects. Nonetheless, it is 
not possible to consider that this allele is the only responsible for symmetric distribution 
of atrophy: even though asymmetric patients did not possess any ε4 alleles, its 
69  
prevalence in the symmetric patients was 50%, and one of the three symmetric patients 
was ε4-/-.  
An influence of the ε4 allele on the symmetric phenotype cannot be ruled out, but a 
subsequent VBM study was undertaken in order to better evaluate its real contribution 
to brain morphology in the individuals affected by FTD. 
Unfortunately, patients in this study are very few in number, and the following 
observations will definitely need to be replicated in larger samples. 
 
 
6.4.1 Effects of the ε4 allele on brain morphology of demented patients: evidence from 
the literature 
 
The genetic asset (the presence of ApoE ε4 allele) is consistent with a theory of greater 
brain vulnerability in ε4 carriers. The greater frequency of the ε4 allele might be at least 
in part responsible for greater and symmetric atrophy, as well as a younger age at onset. 
Smaller brain volumes in normal and AD subjects carrying the ε4 allele have repeatedly 
been addressed (Berg et al., 1998), as well as reduced asymmetry (Lehtovirta et al., 
2000). In addition, the ε4 allele might contribute to the younger age at onset(Berg et al., 
1998), although this effect in FTD is more controversial (Minthon et al., 1997; 
Pickering-Brown et al., 2000). Indeed, the identification of different polymorphisms of 
the ApoE itself suggests that the interaction of this gene with the clinical phenotypes 
might be particularly complex (Zill et al., 2001). 
 
 
6.4.2 APOE and modulation of the effects of the AD and FTD 
 
In the VBM study, carried out to examine the role of APOE, carriers of the ε4 allele 
were separated from the non carriers in both the AD and FTD groups. The results 
indicated that the carriers had greater atrophy in the regions typically affected in each 
condition: frontotemporal areas in FTD, medial-temporal regions in AD, almost as if the 
effect of the ε4 allele consisted of amplifying the effects of the disease. The ε4 allele is 
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widely known to be a risk factor for AD. Our results favor the hypothesis of a similar 
role in FTD, but data in the literature are contrasting. 
 
 
6.4.2.1 Neurophysiologic hypotheses for the detrimental effect of ε4 
 
The particularly high prevalence of ε4 alleles in the small sample of patients with 
symmetric atrophy is compatible with subsequent VBM findings of greater right lobar 
atrophy of the patients carrying the allele compared to the non carriers, characterized by 
left atrophy (Study III) as frequently observed in FTD.  
Different pathways can be hypothesized to explain the observed modulation of the ε4 
allele of APOE on brain atrophy. The first effect seems to be a rather general increase in 
brain vulnerability, as is apparent in both AD and FTD groups. The greater brain 
vulnerability of the subjects carrying the ε4 allele might be explained by lower efficacy 
to carry out repair mechanisms (Weisgraber and Mahley, 1996). This effect is consistent 
with the hypothesis that ε4 is the ancestral human APOE allele (Mahley and Ral, 1999), 
from which the others have evolved in the direction of prolonging healthy ageing (Finch 
and Sapolsky, 1999). 
More complex effects are also plausible in the role of ε4 of modulating brain atrophy. A 
different brain morphology is demonstrated even in the healthy carriers, and points to a 
direct role for APOE in the development of these regions. This role is plausible in the 
light of recent data indicating that receptors for the LDL bind both Reelin, a signaling 
protein that regulates neuronal migration during brain development and ApoE (Weeber 
et al., 2002). The perfusion of mouse hippocampal slices with Reelin significantly 
enhanced long term potentiation (LTP) in CA1, indicating that this protein controls 
synaptic plasticity in the adult brain. Different isoforms of ApoE compete differently 
with Reelin. The ε4 derived APOE protein has greater affinity, and this binding 
contrasts with Reelin’s effects of facilitating LTP and brain plasticity. 
Reduced neural sprouting has indeed been demonstrated to be associated with the ε4 
allele of APOE not only in cultured neurons but also in AD patients (Finch and 
Sapolsky, 1999). 
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The ε4 allele might thus have an effect in modulating brain plasticity in the adult brain, 
but, given the described interaction with Reelin receptors and the demonstrated reduced 
neural sprouting, it is plausible that it can induce gross or subtle differences in brain 
morphology even during the early stages of development. An interaction of these effects 
with other detrimental consequences of specific diseases or genetic conditions might 
explain why the greater atrophy exhibits differential localization in the different 
diseases: medio-temporal in AD, frontotemporal in FTD. 
 
 
6.5 Frontotemporal dementia as a neural system disease 
 
Finally, the VBM study examining the whole pattern of atrophy in FTD detected the 
involvement of the whole rostral limbic system, consisting in the anterior cingulate, 
orbitofrontal and anterior insular cortex, ventral striatum, amygdale and periaqueductal 
grey (Study V). 
Atrophy of the anterior cingulate and orbitofrontal cortices has been found in previous 
neuroimaging studies (Rosen et al., 2002) and atrophy of the amygdalae and striatum in 
pathological studies (Filley et al., 1994). To our knowledge, the insular cortex and the 
periaqueductal gray have never been reported to be atrophic. Beyond the novel notion of 
atrophy in these structures, it is relevant to consider what the present data add to current 
hypotheses on FTD: involvement of these structures points to damage of an entire 
system, which can in effect account for the apparently heterogeneous symptoms of 
FTD. 
The rostral limbic system is a limbic circuit involved in the control of the organism’s 
behavioral outputs, and is based on the specific connections of the affective and 
cognitive divisions of the anterior cingulate cortex, that includes Brodmann areas 25, 33 
and rostral 24, responsible for affective functions, and caudal areas 24 and 32, carrying 
out cognitive functions mainly of response selection (Devinsky et al., 1995; Botvinick 
et al., 2001). This structure integrates the heterogeneous information from (and to) the 
amygdala, the periaqueductal gray, the ventromedial and anterior insular cortices, and 
the ventral striatum (Devinsky et al., 1995; Vogt et al., 1992). The rostral limbic system 
is involved in processing the environmental information to the organism’s benefit, in 
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order to monitor or program the behavioral output compatible with survival (Damasio, 
1998).  
This complex function can be performed thanks to the output of a central structure, the 
amygdala, which processes the value of internal and external stimuli, represents these 
values in the form of emotion to the brain and to subjective experience, and 
permanently associates this emotion to external stimuli (associative learning) (Calder et 
al., 2001; Clark, 1995; Gallagher and Holland, 1994; Rolls 2000a). The ventral striatum 
and the ventromedial prefrontal cortices contribute to this function by allowing reversal 
conditioning (i.e. association of the external stimulus with a different – even opposite – 
reward value that follows environmental changes), which does not occur in the 
amygdala (Rolls, 2000a; Rolls 2000b; Schoenbaum et al., 2000; Setlow et al., 2003), 
before programming and performing the consequent behavioral outputs (Cardinal et al., 
2002; Cardinal et al., 2001). The first and primitive processing of such motor output 
comes from the periaqueductal gray, also closely connected to the amygdala, that 
activates different innate strategies for coping with the environment based on primitive 
attack-escape reactions (Misslin, 2003). The amygdala has also a role in eating behavior 
(Gallagher and Holland, 1994) which, together with the behavioral symptoms belonging 
to the clusters of “social awareness”, was the symptom best distinguishing FTD from 
Alzheimer’s disease in a systematic neuropsychiatric study (Bozeat et al., 2000). 
Hyperorality is one of the classical Klüver-Bucy-like symptoms which have long been 
associated with amygdaloid damage, and are characteristic for FTD as defined by the 
consensus criteria of the Lund and Manchester groups (Lund and Manchester Groups, 
1994). Moreover, the amygdala, in close connection with the ventromedial prefrontal 
and anterior cingulate cortices, influences other higher order functions such as decision 
making (Damasio, 1996; Rolls 200a; Rolls 200b) and theory of mind tasks (Stone et al., 
2003) which have recently been demonstrated to be severely impaired in FTD (Gregory 
et al., 2002). 
If we wish to dissect the concept of “appropriate behavior”, and try to define it 
comprehensively, starting from internal stimulus or potential external input, via all the 
mechanisms of evaluation, filtering, selection, execution, etc. to the resulting output - 
correct behavior in a given situation - this might be too ambitious a task from the point 
of view of this study. Instead, it is proposed to proceed through the atrophic structures 
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of the rostral limbic system to some extent, and to contemplate their individual 
contributions to the global function of the system and to the behavioral disturbances 
observed in FTD.  
The largest areas of atrophy in this study were observed in the anterior cingulate and in 
the ventromedial prefrontal cortex bilaterally.  
The main function of the anterior cingulate cortex consists of the detection of conflict 
within the ongoing information processing. Conflict detection is fundamental in order to 
activate the appropriate executive functions that allow an aware processing of the 
stimuli, strategy shift, and other superior functions that enhance information processing 
when routine processing is not sufficient (Devinski et al, 1995; Botvinick et al., 2001). 
This function can be carried out by virtue of the property of the anterior cingulate of 
integrating the heterogeneous information there converging from the different structures 
of the circuit (Devinski et al, 1995; Botvinick et al., 2001; Vogt, 1992; Adolphs, 2001). 
Subsequent to conflict detection, the anterior cingulate cortex has also a critical role in 
the process of response selection (Devinski et al, 1995; Botvinick et al., 2001). 
Pathology in the anterior cingulate could in part explain also other non-behavioral but 
diagnostic features of FTD, such as mutism and low or labile blood pressure (Persinger, 
2001), via dysregulation of the endocrine and autonomic nervous systems (Devinski et 
al, 1995) as well as its connection with other RLS structures also involved in these 
functions, as described below.  
With respect to the ventromedial prefrontal cortex, this is the main region coupling 
affective information and the mechanisms of action selection. It is of particular 
importance in evaluating and weighing the outcome (reward vs. punishment) related 
with a given choice. Individuals with ventromedial damage may perform normally in 
some frontal tests, such as the Wisconsin Card Sorting Test, but are impaired in their 
choices, tending to choose what produces an immediate and large reward, but in the 
long run leads to even larger punishment or larger net losses in a given paradigm 
(Schoenbaum et al., 2000; Damasio, 1998; Rosen et al., 2002). This is in line with the 
impulsivity and deficits in selection observed in patients with FTD.  
Within the ventromedial prefrontal cortex, the gyrus rectus, that has been associated 
with some conditions with a behavioral component such as Tourette syndrome 
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(McAbee et al., 1999) and autism (Siegel et al., 1992), can explain similar features often 
observed in FTD.  
The particularly close connection of the ventromedial prefrontal cortex with the 
amygdala (Szeszko, 1999) is compatible with “autistic” symptoms as well as with the 
impairment in the “theory of mind” (ToM) which has been demonstrated to be severe in 
both autism and FTD (Gregory et al., 2002). The theory of mind refers to the ability to 
put oneself in other people’s position, and to be able to infer other people’s mental 
states, thoughts and feelings. A failing in this ability means that one will encounter 
difficulties in social interactions with other individuals.  
The performance in the theory of mind tasks in patients with FTD has been shown to 
correlate with ventromedial atrophy in MRI when the amount of atrophy was 
qualitatively rated (Gregory et al., 2002) but the authors themselves state that other key 
structures for the ToM tasks, like the amygdala (Stone et al., 2003), were not 
considered.  
The amygdala in fact was found to be atrophic in our sample. This is the most seminal 
structure in understanding, experiencing, and storage of emotional significance of 
events. In that role it processes the emotional content of events and mediates the 
subsequent behavioral, autonomic and endocrine responses.  
The contributions of anterior insula to cognition and behavior include awareness of 
oneself (Damasio, 1998), damage of which may be observed as a loss of insight. The 
anterior insula, according to the somatic markers hypothesis, is a key structure for 
keeping emotion in check by the organism and it belongs to the system which is 
activated according to the somatic markers hypothesis (Damasio, 1995; Damasio, 
1998). Beyond the typical aberrant behaviors, autonomic dysregulation due to insular 
damage may be responsible for other features such as the low or labile blood pressure 
(Miller et al, 1997) observed in FTD patients. Moreover, the insula subserves emotion 
recognition, particularly that of disgust (Adolphs, 2001; Calder et al., 2001), eating 
behaviors, which are commonly altered in FTD, as well as impairments in linguistic 
functions, in part explaining the mutism observed in FTD (Shuren et al., 1993; Habib et 
al, 1995).  
Turning to the ventral striatum, it has been demonstrated to be involved in disgust 
perception (Calder et al., 2001), conditioning, inhibition of impulsive behavior 
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(Cardinal et al., 2002; Cardinal et al., 2001) conditioning behavioral expression 
(Cardinal et al., 2001; Adolphs, 2002), and context-dependent action selection 
(Lawrence et al., 2000) but its function can perhaps be better described as the final, 
concrete component of the motor output control as tuned by the whole rostral limbic 
system.  
Finally, the periaqueductal gray integrates signals from the body in order to activate 
different innate strategies for coping with the environment (Lawrence et al., 2000). It 
also seems to have a role in language output, as revealed by clinical studies (Esposito et 
al., 1999).  
There were other regions experiencing atrophy e.g. minor changes outside the rostral 
limbic system. These included a small cluster in the Broca’s area, which may be related 
with the language disorder in FTD. On the left side, there were small areas of atrophy 
on the superior, middle and inferior frontal gyri. These are part of the dorsolateral 
prefrontal cortex, whose pathology may contribute to the clinical picture of executive 
dysfunction observed in FTD. Another isolated area of atrophy was found in the left 
inferior temporal gyrus.  
 
 
6.6 Comparison with previous research 
 
Newness of this study, compared to previous research, consists, first of all, in detection 
of atrophy in structures previously undetected in vivo, like the insula and the 
periaqueductal grey matter. This result was allowed by the use of VBM, which allows 
to compare all cerebral districts in one comparison, at the voxel level. Moreover, this 
kind of comparison allowed to gather the atrophic structures into one functional system 
that is hypothesized to be selectively impaired in FTD. This is not possible with the 
classical ROI approach, that provides information about morphometry of a chosen 
structure, but does not allow to know anything about all of the others, be they 
functionally connected or not. 
Only one VBM study was previously conducted on FTD patients by Rosen and 
colleagues (Rosen et al., 2002). In 8 patients, at p<0.05 corrected, they found atrophy in 
the ventromedial frontal cortex, anterior insular and cingulate cortices, and in two 
clusters corresponding to the dorsolateral and premotor frontal cortices. These regions 
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are among those found to be atrophic also in our study. The presence of fewer atrophic 
regions in Rosen et al.’s study might be due to at least two reasons: first, their patients 
seem to be more mildly affected than our own (MMSE 23 vs 14), and second, the 12 
mm filter that they used might have reduced the sensitivity for the detection of atrophy 
in small structures. Unfortunately, the authors did not report the size of the clusters of 
atrophy, and further comparisons between the two studies can not be performed. In our 
study, the cluster size of the dorsolateral prefrontal and premotor cortex was extremely 
small at p<0.05 corrected (see Table 9), while the anterior insula, anterior cingulate and 
ventromedial frontal gyri corresponded to larger clusters.  
 
 
6.7 Main finding of the work 
 
Data from this work suggest a unifying model that can account for the whole syndrome 
of FTD. Indeed, the rostral limbic system, which controls adaptive behavior, is entirely 
impaired in the FTD patients examined, and this impairment can account for the 
complex behavioral syndrome observed in this patients. On the other side, the finding 
might be considered as secondary to the clinical diagnosis of FTD, which relies on such 
behavioral disturbances. Future research, studying patients selected based on 
neuropathological characterization according to the most recent criteria (McKhann et 
al., 2001) will allow to understand whether this system is impaired due to the biological 
changes that define the disease, or whether the clinical features consisting in behavioral 
aberrations are just overlapping among very different conditions, that variably affect the 
rostral limbic system. In this case, impairment of this system would be found due to a 
“circular” reasoning, selecting patients with behavioral aberrations as carriers of the 
studied disease.. 
Since FTD is categorized as a FTLD together with SD and PA, one might wonder 
whether the rostral limbic system might be involved also in SD and PA. The different 
phenotypes of the three conditions do not support this hypothesis in that comprehension 
and production of verbal language, primarily impaired in SD and PA respectively, do 
not seem to rely on the integrity of the rostral limbic system. However, since symptoms 
typical of FTD such as frontal behavioral disturbances can develop also in the more 
advanced stages of SD and PA (Neary et al., 1998) and atrophic regions are partly 
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overlapping (Rosen et al., 2002), this hypothesis cannot be definitely ruled out. Maybe, 
“enlargement” of the rostral limbic system, possibly including other circuits very 
closely connected at a functional level, might account for these similar syndromes. One 
possible hypothesis might hint to the mirror neurons system. These sets of neurons, first 
described by the group of Rizzolatti in 1989 (di Pellegrino et al., 1992; Gallese et al, 
1996), are hypothesized to be involved in emotion comprehension (Gallese et al., 2004), 
but also, for example, in language production and comprehension (Arbib, 2005), that 
are respectively impaired in PPA and in SD. It is possible that such system might be 
differentially involved in the different subtypes of FTLD, and, combined with the 
relative involvement of the RLS, give rise to the different clinical syndromes. This 
hypothesis is highly speculative, although it might suggest future directions for 
research. 
 
 
6.7 Limitations of the work 
 
General limitations of the study involve the very limited number of subjects, and the 
single dataset investigated. Replication of these findings in different, and possibly 
larger, patient samples should be carried out to credit our results. In addition, the 
heterogeneity of sociodemographic features of our subjects forced to statistically 
intervene to make the data comparable. FTD patients were younger than AD ones and 
than controls, and more often men. Of course, statistical expedients, such as 
computation of W-scores, have been adopted in order to reduce the effect of intervening 
variables such as age and sex, nonetheless these procedures are palliative solutions for 
this kind of problem. 
In greater detail, this study was carried out in a limited number of subjects. W-scores for 
asymmetry were computed with a regression model based on a relatively small group of 
controls (10 males and 17 females) and 2 covariates (age and gender). A statistical rule 
of thumb dictates that at least 10 subjects per covariate are the minimum to obtain 
reasonably stable estimates. We might therefore be relatively satisfied by the control 
group, but it must be recognized that since we had only 10 FTD patients, this might 
have led to unstable estimates of sensitivity and specificity values, capitalizing on 
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chance fluctuations. Further studies with larger groups are warranted in the future to 
provide the necessary cross validation. 
Second, we considered our 10 FTD patients as a single group, while it is now clear that 
FTD can have a heterogeneous distribution of pathology and clinical manifestations. 
This view is consistent with our findings of higher standard deviation in all structures in 
FTD patients (average SD=2.1, range between 1.4 and 3.3) compared to AD (average 
SD=1.5, range between 0.7 and 2.8) and might account for those situations where 
greater atrophy seems to be present in FTD but it is not significantly different from AD 
due to the high standard deviation values in FTD (see for example the left temporal 
horns, Table 4).  
Third, we did not record accurately all of the behavioral symptoms of our demented 
patients and their severity. Such information would have been particularly relevant for 
studies II and V, where a link was sought between brain morphology and the behavioral 
aberrations characterizing FTD. Therefore, some of our hypotheses, like that of 
disruption of a fronto-limbic connection drawn from the volumetry of the amygdalae, 
are speculative. For example, we have not systematically recorded behavioral and 
Klüver-Bucy-like symptoms in our patients, and cannot test it systematically. However, 
the clinical criteria that we used to isolate patients with FTD are devised in a way that 
they indirectly lend support to such hypotheses. The typical Klüver-Bucy symptoms 
comprise bulimia, hyperorality, hypersexuality, an irresistible impulse to touch objects, 
and a loss of normal fear and anger (Klüver and Bucy, 1997; Lilly et al., 1983). Most of 
these are included in the clinical criteria for FTD (Neary et al., 1998), and it is accepted 
that these patients show these symptoms early (Neary et al., 1998; Carroll et al., 2001) 
while in AD patients they occur later in the disease course (Förstl et al., 1993). 
Therefore, it is very likely that our FTD patients had more Klüver-Bucy, as well as 
other behavioral symptoms than the AD patients, although accurate recording is lacking 
in our study. Moreover the other clinical tests, investigating disease severity (CDR, 
MMSE) might not be the elective choice for this kind of dementia, in that they are 
primarily designed to stage disease severity in AD, which is clinically very different. 
Indeed, appropriate testing for evaluating disease severity in FTD can hardly be defined, 
and research in this direction is warranted in future work. 
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Finally, none of our patients underwent autopsy, and replication of these findings in 
pathology-proven FTD patients is necessary. Nonetheless, when diagnoses are carried 
out by expert clinicians, a specificity of 99% has been observed, at pathological 
diagnosis (Knopman et al., 2005). 
 
 
6.8 Future studies 
 
Future studies should, first of all, include larger patients group.  
More accurate registration of behavioral symptoms could allow us to formulate more 
certain conclusions about the pathogenesis of behavioral aberrations, permitting precise 
correlations with discrete structures or identifying the involvement of wider circuits as 
already hinted at in these studies.  
The evolution of MR techniques for image preprocessing and comparisons will also 
make it possible to carry out analogous studies on more solid theoretical grounds. For 
example, VMB analyses can now be carried out with new software, so called SPM2, 
that differs from SPM99 in that it allows more accurate image preprocessing and is 
based on Bayesian probability. This last characteristic aids in the statistical analyses 
without the assumptions required by parametric statistics. Tests with a low number of 
subjects, or even single-case analysis, can be appropriately carried out. Adoption of 
such a tool might highlight patterns of atrophy in “each” patient with FTD, and this 
would aid in assessing the degree of the generalizability of results obtained from groups 
of patients.  
Confirmation of previous results with these kinds of tools, and possibly in single 
subjects, would also boost accurate diagnosis, allowing early detection of a very 
specific pattern of atrophy. This application would be of great clinical importance.  
Finally, replication in autopsy confirmed cases would increase the reliability of the 
neuroimaging results.  
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7. CONCLUSIONS 
 
This study investigated two main fields of interest in FTD studies with MRI: that of the 
morphological characterization of the brain of these patients, mainly aimed at helping in 
the diagnosis and differential diagnosis from other kinds of dementias, and that of the 
tentative explanation of the clinical symptoms of the disease. 
 
In summary: 
1) The structures typically atrophic in FTD were also atrophic in AD although to a 
lesser degree, and vice-versa, preventing accurate differential diagnosis based on the 
volume of single structures. 
2) The differential diagnosis from AD was greatly improved by a compounded 
biological marker, including a set of brain structures typically involved in both diseases. 
3) Laterality information was particularly informative, in that FTD is a particularly 
“asymmetric” disorder 
4) However, asymmetry is not found in 100% of FTD patients. A minority of them 
exhibit a clearly symmetric atrophy, that is accompanied by a greater severity of 
neurodegeneration, younger age at onset and presence of the ε4 allele of APOE. 
5) The APOE ε4 allele is not recognized as a risk factor for FTD, but seems to modulate 
neurodegeneration by increasing brain susceptibility to the effects of the disease 
6) Single structure atrophy, which is insufficient for the differential diagnosis, is also 
unsatisfactory in the explanation of clinical symptoms: similar amygdaloid atrophy was 
found in AD and FTD, but these have disproportionately more amygdaloid-related 
symptoms 
7) Wider brain circuits should be considered for the explanation of the clinical 
symptoms. In particular, the amygdaloid-related symptoms might be better explained by 
disruption of fronto-limbic connections.  
8) FTD might be a consequence of disruption not only of fronto-limbic connections, but 
also of a wider circuit at control of behavior, the rostral limbic system, that includes also 
other limbic structures. The involvement of this whole system, as observed in the VBM 
analyses, might account for the clinical manifestations of this disease.  
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